<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02630459</url>
  </required_header>
  <id_info>
    <org_study_id>20120309</org_study_id>
    <nct_id>NCT02630459</nct_id>
  </id_info>
  <brief_title>A Safety and Efficacy Study to Evaluate AMG 334 in Migraine Prevention</brief_title>
  <official_title>A Phase 2, Randomized, Double-blind, Placebo-controlled Study to Evaluate the Efficacy and Safety of AMG 334 in Migraine Prevention</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Amgen</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Amgen</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>Yes</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      Randomized, double-blind, placebo-controlled, parallel-group, multicenter study followed by&#xD;
      an open-label treatment phase (OLTP). To evaluate the effect of erenumab (AMG 334) compared&#xD;
      to placebo on the change from baseline in monthly migraine days.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This is a Phase 2, randomized, double-blind, placebo-controlled study in participants with&#xD;
      episodic migraine. The study's double blind treatment phase (DBTP) is designed to evaluate if&#xD;
      treatment with erenumab once a month for 6 months compared with placebo is effective in&#xD;
      reducing the mean monthly migraine days. Additionally, this study will continue to evaluate&#xD;
      the efficacy and safety of erenumab during the OLTP where participants will continue to&#xD;
      receive active treatment monthly.&#xD;
&#xD;
      The study also includes a clinical home use (CHU) sub-study to assess a participant's ability&#xD;
      to self-administer 140 mg of erenumab. Participants will be randomized 1:1 to use either 2&#xD;
      pre-filled 70 mg/mL autoinjector (AI)/pens or 1 pre-filled 140 mg/mL AI/pen. Participation in&#xD;
      the substudy is optional, and no additional samples will be collected for the sub-study.&#xD;
&#xD;
      After implementation of Protocol Amendment 2, the dose of erenumab in the OLTP increased from&#xD;
      70 mg to 140 mg QM. Participants who had already completed week 48 remain on 70 mg QM,&#xD;
      participants not yet starting the OLTP, or not yet completing the week 48 visit receive&#xD;
      erenumab 140 mg QM for the remainder of the OLTP.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">January 6, 2016</start_date>
  <completion_date type="Actual">June 5, 2019</completion_date>
  <primary_completion_date type="Actual">September 25, 2017</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>Triple (Participant, Care Provider, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Change From Baseline in Mean Monthly Migraine Days at Months 4, 5 and 6</measure>
    <time_frame>4-week baseline phase and months 4, 5 and 6 of DBTP.</time_frame>
    <description>A migraine day was defined as any calendar day in which the participant experienced a qualified migraine headache (onset, continuation or recurrence of the migraine headache). A qualified migraine headache was a migraine with or without aura, lasting for ≥ 30 minutes, and meeting at least one of the following criteria: a) ≥ 2 of the following pain features: unilateral, throbbing, moderate to severe, exacerbated with exercise/physical activity; b) ≥ 1 of the following associated symptoms: nausea and/or vomiting, photophobia and phonophobia. Change from baseline was calculated using the mean monthly migraine days from months 4, 5 and 6 of the DBTP minus the number of migraine days during the 4-week baseline phase. Least squares (LS) mean was estimated using a generalized linear mixed model which included treatment, visit, treatment by visit interaction, stratification factor (current, prior only, or no prior/current treatment), and baseline value as covariates.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>CHU Sub-Study: Participant-Reported Outcome of Attempted Full-Dose Administration at Day 29 (Week 4) and Day 57 (Week 8)</measure>
    <time_frame>CHU day 29 (week 4) and day 57 (week 8)</time_frame>
    <description>On CHU day 29 and day 57, site staff interviewed sub-study participants and asked if they administered a full, partial, or no dose of erenumab (after explaining that a full dose means that the entire volume of the AI/pen was injected) and documented the participant's response in the electronic case report form. Data presented are the percentage of participants who reported &quot;full administration,&quot; &quot;not full administration,&quot; or &quot;discontinued investigational product (ie, no dose).&quot; (Day 1 of the CHU substudy occurred at any OLTP study visit [up to week 88] as long as the participant had previously received at least 1 OL dose of erenumab 140 mg.)</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Percentage of Participants With at Least a 50% Reduction From Baseline in Mean Monthly Migraine Days at Months 4, 5 and 6</measure>
    <time_frame>4-week baseline phase and months 4, 5 and 6 of DBTP.</time_frame>
    <description>A migraine day was defined as any calendar day in which the participant experienced a qualified migraine headache (onset, continuation or recurrence of the migraine headache). A qualified migraine headache was a migraine with or without aura, lasting for ≥ 30 minutes, and meeting at least one of the following criteria: a) ≥ 2 of the following pain features: unilateral, throbbing, moderate to severe, exacerbated with exercise/physical activity; b) ≥ 1 of the following associated symptoms: nausea and/or vomiting, photophobia and phonophobia.&#xD;
At least a 50% reduction from baseline in monthly migraine days was determined if: (mean monthly migraine days over the last three months of the DBTP minus baseline monthly migraine days) * 100 / baseline monthly migraine days, was less than or equal to -50%.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in Mean Monthly Acute Migraine-Specific Medication Treatment Days at Months 4, 5 and 6</measure>
    <time_frame>4-week baseline phase and months 4, 5 and 6 of DBTP.</time_frame>
    <description>An acute migraine-specific medication treatment day was defined as any calendar day during which the participant took a migraine-specific medication (ie, triptan or ergotamine-derivatives).&#xD;
The change from baseline was calculated using the mean monthly acute migraine-specific medication treatment days over the last three months (months 4, 5 and 6) of the DBTP minus the baseline monthly acute migraine-specific medication treatment days.&#xD;
LS mean was estimated using a generalized linear mixed model which included treatment, visit, treatment by visit interaction, stratification factor (prior/current treatment), and baseline value as covariates.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants With Treatment Emergent Adverse Events (TEAEs), Serious TEAEs, Discontinuations Due to TEAEs, and Fatal TEAEs During the DBTP</measure>
    <time_frame>From first dose of IP up to week 24</time_frame>
    <description>An adverse event (AE) is defined as any untoward medical occurrence in a clinical trial participant. A serious adverse event (SAE) is defined as an adverse event that meets at least 1 of the following serious criteria: fatal; life threatening; requires in-patient hospitalization or prolongation of existing hospitalization; results in persistent or significant disability/incapacity; congenital anomaly/birth defect; other medically important serious event. Events were graded according to the National Cancer Institute Common Terminology Criteria for Adverse Events (NCI CTCAE) version 4.03 (grade 1=mild, grade 2=moderate, grade 3=severe, grade 4= life-threatening, grade 5=death).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants With TEAEs, Serious TEAEs, Discontinuations Due to TEAEs, and Fatal TEAEs During the OLTP</measure>
    <time_frame>From first dose of IP in the OLTP (week 24) through the end of the OLTP (week 100) plus 12 weeks</time_frame>
    <description>An AE is defined as any untoward medical occurrence in a clinical trial participant. An SAE is defined as an adverse event that meets at least 1 of the following serious criteria: fatal; life threatening; requires in-patient hospitalization or prolongation of existing hospitalization; results in persistent or significant disability/incapacity; congenital anomaly/birth defect; other medically important serious event. Events were graded according to the NCI CTCAE version 4.03 (grade 1=mild, grade 2=moderate, grade 3=severe, grade 4= life-threatening, grade 5=death).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants With TEAEs, Serious TEAEs, Discotninuations Due to TEAEs, Fatal TEAEs, and Adverse Device Effects During the CHU Sub-Study</measure>
    <time_frame>CHU sub-study day 1 through day 85 (end of CHU sub-study). Day 1 of the CHU substudy occurred at any OLTP study visit (up to week 88) as long as the participant had previously received at least 1 OL dose of erenumab 140 mg.</time_frame>
    <description>An AE is defined as any untoward medical occurrence in a clinical trial participant. An SAE is defined as an adverse event that meets at least 1 of the following serious criteria: fatal; life threatening; requires in-patient hospitalization or prolongation of existing hospitalization; results in persistent or significant disability/incapacity; congenital anomaly/birth defect; other medically important serious event. Events were graded according to the NCI CTCAE version 4.03 (grade 1=mild, grade 2=moderate, grade 3=severe, grade 4= life-threatening, grade 5=death). TEAEs leading to discontinuation of IP are TEAEs leading to complete discontinuation of erenumab regardless of CHU IP or parent study IP.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants With Post-Baseline Liver Function Test Abnormalities During the DBTP</measure>
    <time_frame>From the first dose of study IP through the end of the DBTP (up to week 24)</time_frame>
    <description>Post-baseline is defined as any assessment done after the first dose of IP. Liver Function tests included alkaline phosphatase (ALP), alanine aminotransferase (ALT), aspartate aminotransferase (AST), and total bilirubin (TBL). ULN=upper limit of normal.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants With Post-Baseline Liver Function Test Abnormalities During the OLTP</measure>
    <time_frame>From the first dose of OLTP IP (week 24) through the end of the OLTP (up to week 100)</time_frame>
    <description>Post-baseline is defined as any assessment done after the first dose of OLTP IP. Liver Function tests included alkaline phosphatase (ALP), alanine aminotransferase (ALT), aspartate aminotransferase (AST), and total bilirubin (TBL). ULN=upper limit of normal.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants With Blood Pressure Changes From Baseline in Categories at Week 24 During the DBTP</measure>
    <time_frame>Baseline (last assessment prior to first dose of IP), week 24</time_frame>
    <description>Participants with increases (↑) from baseline (BL) in diastolic blood pressure (DBP) and systolic blood pressure (SBP) at week 24 (Wk24) are presented.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants With Blood Pressure Changes From Pre-OLTP Baseline in Categories at Week 100 During the OLTP</measure>
    <time_frame>Pre-OLTP Baseline (last assessment prior to first dose of IP in OLTP), week 100</time_frame>
    <description>Participants with increases (↑) from baseline (BL) in diastolic blood pressure (DBP) and systolic blood pressure (SBP) at week 100 (Wk100) are presented.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants With Anti-Erenumab Antibodies During the Entire Study for Participants Who Received ≥ 1 Dose of Erenumab</measure>
    <time_frame>Baseline (first dose of erenumab) up to end of study (week 100) plus 12 weeks</time_frame>
    <description>Data are summarized by the treatment participants received during the double-blind treatment phase. Placebo participants may have received erenumab 70 mg or 140 mg during the OLTP. Baseline is defined as the last antibody assessment on or prior to the first dose of erenumab.&#xD;
Transient binding/neutralizing antibody responses are defined as a negative (neg) result at the participant's last timepoint tested among participants who developed binding/neutralizing antibodies post-baseline.</description>
  </secondary_outcome>
  <number_of_arms>7</number_of_arms>
  <enrollment type="Actual">475</enrollment>
  <condition>Migraine</condition>
  <arm_group>
    <arm_group_label>Double Blind Treatment Phase (DBTP): Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Participants received placebo by subcutaneous injection on day 1 and at weeks 4, 8, 12, 16, and 20 in the double-blind treatment phase.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>DBTP: Erenumab 28 mg QM</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants received erenumab 28 mg by subcutaneous injection on day 1 and at weeks 4, 8, 12, 16, and 20 in the double-blind treatment phase.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>DBTP: Erenumab 70 mg QM</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants received erenumab 70 mg by subcutaneous injection on day 1 and at weeks 4, 8, 12, 16, and 20 in the double-blind treatment phase.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>DBTP: Erenumab 140 mg QM</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants received erenumab 140 mg by subcutaneous injection on day 1 and at weeks 4, 8, 12, 16, and 20 in the double-blind treatment phase.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Open-Label Treatment Phase (OLTP): Erenumab 70-140 mg QM</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants received an erenumab dose of 70 and/or 140 mg QM SC (depending on the participant's visit completion status after Institutional Review Board [IRB] approval of Protocol Amendment 2) in the OLTP for a total of 76 weeks.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>CHU Sub-Study: Two 70 mg/mL AI/pens</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>A subset of participants in the OLTP randomized to self administer erenumab via two 70 mg/mL autoinjector (AI)/pens on day 29 and day 57 of the CHU Sub-Study</description>
  </arm_group>
  <arm_group>
    <arm_group_label>CHU Sub-Study: One 140 mg/mL AI/pen</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>A subset of participants in the OLTP randomized to self administer erenumab via one 140 mg/mL AI/pen on day 29 and day 57 of the CHU Sub-Study</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>placebo via subcutaneous injection</description>
    <arm_group_label>Double Blind Treatment Phase (DBTP): Placebo</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Erenumab</intervention_name>
    <description>erenumab via subcutaneous injection</description>
    <arm_group_label>DBTP: Erenumab 140 mg QM</arm_group_label>
    <arm_group_label>DBTP: Erenumab 28 mg QM</arm_group_label>
    <arm_group_label>DBTP: Erenumab 70 mg QM</arm_group_label>
    <arm_group_label>Open-Label Treatment Phase (OLTP): Erenumab 70-140 mg QM</arm_group_label>
    <other_name>AMG 334, Aimovig™</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Erenumab</intervention_name>
    <description>erenumab via autoinjector (AI)/pen</description>
    <arm_group_label>CHU Sub-Study: One 140 mg/mL AI/pen</arm_group_label>
    <arm_group_label>CHU Sub-Study: Two 70 mg/mL AI/pens</arm_group_label>
    <other_name>AMG 334, Aimovig™</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria to be assessed prior to entering the subject into the initial screening&#xD;
        and/or baseline phase:&#xD;
&#xD;
          -  Provided informed consent prior to initiation of any study-specific&#xD;
             activities/procedures&#xD;
&#xD;
          -  History of migraine (with or without aura) for ≥ 12 months prior to screening&#xD;
             according to the International Headache Society (IHS) Classification The International&#xD;
             Classification of Headache Disorders (ICHD)-3 (Headache Classification Committee of&#xD;
             the IHS, 2013),&#xD;
&#xD;
          -  Migraine frequency: ≥ 4 and &lt; 15 migraine days per month on average across the 3&#xD;
             months prior to screening,&#xD;
&#xD;
          -  Headache frequency: &lt; 15 headache days per month on average across the 3 months prior&#xD;
             to screening.&#xD;
&#xD;
        Inclusion Criteria to be assessed during the baseline phase and confirmed prior to&#xD;
        randomizing the subject into the double-blind treatment phase:&#xD;
&#xD;
          -  Demonstrated at least 80% compliance with the electronic Diary (eDiary),&#xD;
&#xD;
          -  Migraine frequency: ≥ 4 and &lt; 15 migraine days during the baseline phase based on the&#xD;
             eDiary calculations,&#xD;
&#xD;
          -  Headache frequency: &lt; 15 headache days during the baseline phase based on the eDiary&#xD;
             calculations.&#xD;
&#xD;
        Inclusion Criteria for the Clinical Home Use (CHU) Substudy:&#xD;
&#xD;
        - Subjects must have provided informed consent for the substudy. Subjects enrolling in the&#xD;
        CHU substudy must have received open-label 140 mg erenumab for at least 1 dose.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Older than 50 years of age at migraine onset,&#xD;
&#xD;
          -  History of cluster headache or hemiplegic migraine headache,&#xD;
&#xD;
          -  Unable to differentiate migraine from other headaches,&#xD;
&#xD;
          -  No therapeutic response with &gt; 2 of the following 7 medication categories for&#xD;
             prophylactic treatment of migraine after an adequate therapeutic trial: Category 1:&#xD;
             Divalproex sodium, sodium valproate, Category 2: Topiramate, Category 3: Beta blockers&#xD;
             (for example: atenolol, bisoprolol, metoprolol, nadolol, nebivolol, pindolol,&#xD;
             propranolol, timolol), Category 4: Tricyclic antidepressants (for example:&#xD;
             amitriptyline, nortriptyline, protriptyline),Category 5: Serotonin-norepinephrine&#xD;
             reuptake inhibitors (for example: venlafaxine, desvenlafaxine, duloxetine,&#xD;
             milnacipran), Category 6: Flunarizine, verapamil, lomerizine, Category 7: Lisinopril,&#xD;
             candesartan,&#xD;
&#xD;
          -  Used a prohibited medication, device or procedure within 2 months prior to the start&#xD;
             of the baseline phase or during the baseline phase,&#xD;
&#xD;
          -  Received botulinum toxin in the head and/or neck region within 4 months prior to the&#xD;
             start of the baseline phase or during the baseline phase,&#xD;
&#xD;
          -  Taken the following for any indication in any month during the 2 months prior to the&#xD;
             start of the baseline phase: Ergotamines or triptans on ≥ 10 days per month, or Simple&#xD;
             analgesics (nonsteroidal anti-inflammatory drugs [NSAIDs], acetaminophen) on ≥ 15 days&#xD;
             per month, or Opioid- or butalbital-containing analgesics on ≥ 4 days per month,&#xD;
&#xD;
          -  Anticipated to require any excluded medication, device or procedure during the study,&#xD;
&#xD;
          -  Active chronic pain syndromes (such as fibromyalgia and chronic pelvic pain),&#xD;
&#xD;
          -  History of major psychiatric disorder (such as schizophrenia and bipolar disorder), or&#xD;
             current evidence of depression based on a Beck Depression Inventory (BDI)-II total&#xD;
             score &gt; 19 at screening. Subjects with anxiety disorder and/or major depressive&#xD;
             disorder are permitted in the study if they are considered by the investigator to be&#xD;
             stable and are taking no more than 1 medication for each disorder. Subjects must have&#xD;
             been on a stable dose within the 3 months prior to the start of the baseline phase,&#xD;
&#xD;
          -  History of seizure disorder or other significant neurological conditions other than&#xD;
             migraine. Note: A single childhood febrile seizure is not exclusionary,&#xD;
&#xD;
          -  Malignancy within the 5 years prior to screening, except non melanoma skin cancers,&#xD;
             cervical or breast ductal carcinoma in situ,&#xD;
&#xD;
          -  Human immunodeficiency virus (HIV) infection by history,&#xD;
&#xD;
          -  Hepatic disease by history, or total bilirubin (TBL) ≥ 2.0 x upper limit of normal&#xD;
             (ULN) or alanine transaminase (ALT) or aspartate aminotransferase (AST) ≥ 3.0 x ULN,&#xD;
             as assessed by the central laboratory at initial screening, or evidence of acute or&#xD;
             chronic hepatitis B or hepatitis C virus. Hepatitis status will be evaluated by&#xD;
             testing for hepatitis B surface antigen (HepBsAg), total hepatitis B core antibody&#xD;
             (HepBcAb) and hepatitis C antibody by the central laboratory at initial screening.&#xD;
             Polymerase chain reaction (PCR) should be performed to confirm active disease only if&#xD;
             total HepBcAb is positive and HepBsAg is negative or if C antibody is positive,&#xD;
&#xD;
          -  Myocardial infarction, stroke, transient ischemic attack (TIA), unstable angina, or&#xD;
             coronary artery bypass surgery or other revascularization procedure within 12 months&#xD;
             prior to screening,&#xD;
&#xD;
          -  History or evidence of any other unstable or clinically significant medical condition&#xD;
             that, in the opinion of the investigator, would pose a risk to subject safety or&#xD;
             interfere with the study evaluation, procedures or completion,&#xD;
&#xD;
          -  Subject has any clinically significant vital sign, laboratory, or electrocardiogram&#xD;
             (ECG) abnormality during screening that, in the opinion of the investigator, could&#xD;
             pose a risk to subject safety or interfere with the study evaluation,&#xD;
&#xD;
          -  The subject is at risk of self-harm or harm to others as evidenced by past suicidal&#xD;
             behavior or endorsing items 4 or 5 on the Columbia-Suicide Severity Rating Scale&#xD;
             (C-SSRS) assessed at screening,&#xD;
&#xD;
          -  Evidence of drug or alcohol abuse or dependence within 12 months prior to screening,&#xD;
             based on medical records, patient self-report, or positive urine drug test performed&#xD;
             during screening (with the exception of prescribed medications such as opioids or&#xD;
             barbiturates),&#xD;
&#xD;
          -  Pregnant or breastfeeding, or is a female expecting to conceive during the study,&#xD;
             including through 16 weeks after the last dose of investigational product,&#xD;
&#xD;
          -  Female subject of childbearing potential who is unwilling to use an acceptable method&#xD;
             of effective contraception during treatment with investigational product through 16&#xD;
             weeks after the last dose of investigational product,&#xD;
&#xD;
          -  Currently receiving treatment in another investigational device or drug study, or less&#xD;
             than 90 days prior to screening since ending treatment on another investigational&#xD;
             device or drug study(-ies),&#xD;
&#xD;
          -  Known sensitivity to any component of the investigational product (Refer to the&#xD;
             Investigational Product Instruction Manual [IPIM] for details),&#xD;
&#xD;
          -  Previously randomized into an erenumab study,&#xD;
&#xD;
          -  Member of investigational site staff or relative of the investigator,&#xD;
&#xD;
          -  Unlikely to be able to complete all protocol-required study visits or procedures,&#xD;
             and/or to comply with all required study procedures (eg, independent completion of&#xD;
             eDiary items) to the best of the subject's and investigator's knowledge.&#xD;
&#xD;
        Exclusion Criteria for the CHU Substudy:&#xD;
&#xD;
        - Unreliability as a study participant based on the investigator's (or designee's)&#xD;
        knowledge of the subject (eg, unwillingness to adhere to the protocol, unwilling to&#xD;
        self-inject using an autoinjector (AI)/pen after review of the Instructions for Use).&#xD;
        Subjects receiving erenumab 70 mg in the open-label phase are not eligible.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>20 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>MD</last_name>
    <role>Study Director</role>
    <affiliation>Amgen</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Kamogawa-shi</city>
        <state>Chiba</state>
        <zip>296-0041</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Saijo-shi</city>
        <state>Ehime</state>
        <zip>793-0030</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Ota-shi</city>
        <state>Gunma</state>
        <zip>373-8585</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Hiroshima-shi</city>
        <state>Hiroshima</state>
        <zip>730-8518</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Sapporo-shi</city>
        <state>Hokkaido</state>
        <zip>060-0004</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Sapporo-shi</city>
        <state>Hokkaido</state>
        <zip>060-8570</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Sapporo-shi</city>
        <state>Hokkaido</state>
        <zip>063-0005</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Kobe-shi</city>
        <state>Hyogo</state>
        <zip>658-0064</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Tsukuba-shi</city>
        <state>Ibaraki</state>
        <zip>305-8576</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Kahoku-gun</city>
        <state>Ishikawa</state>
        <zip>929-0342</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Morioka-shi</city>
        <state>Iwate</state>
        <zip>020-8505</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Kagoshima-shi</city>
        <state>Kagoshima</state>
        <zip>892-0844</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Kawasaki-shi</city>
        <state>Kanagawa</state>
        <zip>211-8533</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Kawasaki-shi</city>
        <state>Kanagawa</state>
        <zip>211-8588</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Kawasaki-shi</city>
        <state>Kanagawa</state>
        <zip>216-8511</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Kumamoto-shi</city>
        <state>Kumamoto</state>
        <zip>861-2101</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Kumamoto-shi</city>
        <state>Kumamoto</state>
        <zip>862-8505</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Kyoto-shi</city>
        <state>Kyoto</state>
        <zip>600-8811</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Sendai-shi</city>
        <state>Miyagi</state>
        <zip>982-0014</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Osaka-shi</city>
        <state>Osaka</state>
        <zip>556-0017</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Osakasayama-shi</city>
        <state>Osaka</state>
        <zip>589-8511</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Toyonaka-shi</city>
        <state>Osaka</state>
        <zip>560-0012</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Saga-shi</city>
        <state>Saga</state>
        <zip>840-0806</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Iruma-gun</city>
        <state>Saitama</state>
        <zip>350-0495</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Saitama-shi</city>
        <state>Saitama</state>
        <zip>338-8577</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Tokorozawa-shi</city>
        <state>Saitama</state>
        <zip>359-1141</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Shizuoka-shi</city>
        <state>Shizuoka</state>
        <zip>420-0853</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Shimotsuga-gun</city>
        <state>Tochigi</state>
        <zip>321-0293</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Bunkyo-ku</city>
        <state>Tokyo</state>
        <zip>113-8431</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Bunkyo-ku</city>
        <state>Tokyo</state>
        <zip>113-8603</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Chofu-shi</city>
        <state>Tokyo</state>
        <zip>182-0006</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Chuo-ku</city>
        <state>Tokyo</state>
        <zip>104-8560</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Hachioji-shi</city>
        <state>Tokyo</state>
        <zip>192-0032</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Minato-ku</city>
        <state>Tokyo</state>
        <zip>106-6106</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Minato-ku</city>
        <state>Tokyo</state>
        <zip>108-8642</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Shibuya-ku</city>
        <state>Tokyo</state>
        <zip>151-0051</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Shinjuku-ku</city>
        <state>Tokyo</state>
        <zip>160-0017</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Shinjuku-ku</city>
        <state>Tokyo</state>
        <zip>160-8582</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Yonago-city</city>
        <state>Tottori</state>
        <zip>683-8504</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Toyama-shi</city>
        <state>Toyama</state>
        <zip>930-0194</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Toyama-shi</city>
        <state>Toyama</state>
        <zip>930-0803</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Hofu-shi</city>
        <state>Yamaguchi</state>
        <zip>747-0802</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Yamaguchi-shi</city>
        <state>Yamaguchi</state>
        <zip>754-0002</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Kai-shi</city>
        <state>Yamanashi</state>
        <zip>400-0124</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Japan</country>
  </location_countries>
  <link>
    <url>http://www.amgentrials.com</url>
    <description>AmgenTrials clinical trials website</description>
  </link>
  <reference>
    <citation>Sakai F, Takeshima T, Tatsuoka Y, Hirata K, Lenz R, Wang Y, Cheng S, Hirama T, Mikol DD. A Randomized Phase 2 Study of Erenumab for the Prevention of Episodic Migraine in Japanese Adults. Headache. 2019 Nov;59(10):1731-1742. doi: 10.1111/head.13652. Epub 2019 Oct 14.</citation>
    <PMID>31612482</PMID>
  </reference>
  <verification_date>November 2020</verification_date>
  <study_first_submitted>December 11, 2015</study_first_submitted>
  <study_first_submitted_qc>December 11, 2015</study_first_submitted_qc>
  <study_first_posted type="Estimate">December 15, 2015</study_first_posted>
  <results_first_submitted>September 17, 2018</results_first_submitted>
  <results_first_submitted_qc>February 15, 2019</results_first_submitted_qc>
  <results_first_posted type="Actual">March 13, 2019</results_first_posted>
  <last_update_submitted>November 10, 2020</last_update_submitted>
  <last_update_submitted_qc>November 10, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">November 19, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Migraine Prevention</keyword>
  <keyword>Headache</keyword>
  <keyword>Prophylaxis</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Migraine Disorders</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Erenumab</mesh_term>
    <mesh_term>Antibodies, Monoclonal</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Yes</sharing_ipd>
    <ipd_description>De-identified individual patient data for variables necessary to address the specific research question in an approved data sharing request</ipd_description>
    <ipd_info_type>Study Protocol</ipd_info_type>
    <ipd_info_type>Statistical Analysis Plan (SAP)</ipd_info_type>
    <ipd_info_type>Informed Consent Form (ICF)</ipd_info_type>
    <ipd_info_type>Clinical Study Report (CSR)</ipd_info_type>
    <ipd_time_frame>Data sharing requests relating to this study will be considered beginning 18 months after the study has ended and either 1) the product and indication (or other new use) have been granted marketing authorization in both the US and Europe or 2) clinical development for the product and/or indication discontinues and the data will not be submitted to regulatory authorities. There is no end date for eligibility to submit a data sharing request for this study.</ipd_time_frame>
    <ipd_access_criteria>Qualified researchers may submit a request containing the research objectives, the Amgen product(s) and Amgen study/studies in scope, endpoints/outcomes of interest, statistical analysis plan, data requirements, publication plan, and qualifications of the researcher(s). In general, Amgen does not grant external requests for individual patient data for the purpose of re-evaluating safety and efficacy issues already addressed in the product labelling. Requests are reviewed by a committee of internal advisors, and if not approved, may be further arbitrated by a Data Sharing Independent Review Panel. Upon approval, information necessary to address the research question will be provided under the terms of a data sharing agreement. This may include anonymized individual patient data and/or available supporting documents, containing fragments of analysis code where provided in analysis specifications. Further details are available at the link below.</ipd_access_criteria>
    <ipd_url>https://www.amgen.com/datasharing</ipd_url>
  </patient_data>
  <provided_document_section>
    <provided_document>
      <document_type>Study Protocol</document_type>
      <document_has_protocol>Yes</document_has_protocol>
      <document_has_icf>No</document_has_icf>
      <document_has_sap>No</document_has_sap>
      <document_date>June 5, 2017</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/59/NCT02630459/Prot_000.pdf</document_url>
    </provided_document>
    <provided_document>
      <document_type>Statistical Analysis Plan</document_type>
      <document_has_protocol>No</document_has_protocol>
      <document_has_icf>No</document_has_icf>
      <document_has_sap>Yes</document_has_sap>
      <document_date>February 14, 2016</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/59/NCT02630459/SAP_001.pdf</document_url>
    </provided_document>
  </provided_document_section>

  <clinical_results>

    <participant_flow>
      <recruitment_details>The study, initiated on 06 January 2016 at 43 centers in Japan, included a 24-week double-blind treatment phase (DBTP) followed by a 76-week open-label (OL) treatment phase (OLTP).&#xD;
DBTP: participants were randomized 2:1:2:2 to receive placebo, erenumab 28 mg, erenumab 70 mg, or erenumab 140 mg once monthly (QM) subcutaneously (SC).</recruitment_details>
      <pre_assignment_details>OLTP: participants received erenumab 70 mg and/or 140 mg QM SC (depending on the participant's visit completion status after a protocol amendment).&#xD;
Optional 85-day clinical home use (CHU) sub-study during the OLTP: participants randomized 1:1 to erenumab using two 70 mg/mL or one 140 mg/mL autoinjector (AI)/pen(s).</pre_assignment_details>
      <group_list>
        <group group_id="P1">
          <title>DBTP: Placebo</title>
          <description>Placebo SC on day 1 and at weeks 4, 8, 12, 16, and 20 in the DBTP.</description>
        </group>
        <group group_id="P2">
          <title>DBTP: Erenumab 28 mg QM</title>
          <description>Erenumab 28 mg SC on day 1 and at weeks 4, 8, 12, 16, and 20 in the DBTP.</description>
        </group>
        <group group_id="P3">
          <title>DPTP: Erenumab 70 mg QM</title>
          <description>Erenumab 70 mg SC on day 1 and at weeks 4, 8, 12, 16, and 20 in the DBTP.</description>
        </group>
        <group group_id="P4">
          <title>DBTP: Erenumab 140 mg QM</title>
          <description>Erenumab 140 mg SC on day 1 and at weeks 4, 8, 12, 16, and 20 in the DBTP.</description>
        </group>
        <group group_id="P5">
          <title>OLTP: Erenumab 70 mg QM (Initial OL Dose)</title>
          <description>Participants assigned to an initial erenumab dose of 70 mg QM SC in the OLTP.&#xD;
After a protocol amendment, participants who had already completed the week 48 OLTP visit continued to receive OL erenumab 70 mg QM SC for a total of 76 weeks. Participants who had not yet completed the OLTP week 48 visit and were already receiving OL erenumab 70 mg QM SC increased their dose to erenumab 140 mg QM SC, continued until the week 100 visit for a total OLTP duration of 76 weeks.</description>
        </group>
        <group group_id="P6">
          <title>OLTP: Erenumab 140 mg QM (Initial OL Dose)</title>
          <description>Participants assigned to an initial erenumab dose of 140 mg QM SC in the OLTP.&#xD;
After a protocol amendment, participants who had not yet completed the DBTP and were not yet in the OLTP received an initial dose of erenumab 140 mg QM SC upon entering the OLTP, and continued receiving OL erenumab 140 mg QM SC for 76 weeks.</description>
        </group>
        <group group_id="P7">
          <title>CHU Sub-Study: Two 70 mg/mL AI/Pens</title>
          <description>A subset of participants in the OLTP randomized to self-administer erenumab via two 70 mg/mL AI/pens on CHU sub-study day 1, day 29 and day 57.</description>
        </group>
        <group group_id="P8">
          <title>CHU Sub-Study: One 140 mg/mL AI/Pen</title>
          <description>A subset of participants in the OLTP randomized to self-administer erenumab via one 140 mg/mL AI/pen on CHU sub-study day 1, day 29 and day 57.</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Double-Blind Treatment Phase (DBTP)</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="136"/>
                <participants group_id="P2" count="67"/>
                <participants group_id="P3" count="135"/>
                <participants group_id="P4" count="137"/>
                <participants group_id="P5" count="0"/>
                <participants group_id="P6" count="0"/>
                <participants group_id="P7" count="0"/>
                <participants group_id="P8" count="0"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>Received Investigational Product (IP)</title>
              <participants_list>
                <participants group_id="P1" count="136"/>
                <participants group_id="P2" count="66"/>
                <participants group_id="P3" count="135"/>
                <participants group_id="P4" count="137"/>
                <participants group_id="P5" count="0"/>
                <participants group_id="P6" count="0"/>
                <participants group_id="P7" count="0"/>
                <participants group_id="P8" count="0"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="133"/>
                <participants group_id="P2" count="65"/>
                <participants group_id="P3" count="130"/>
                <participants group_id="P4" count="134"/>
                <participants group_id="P5" count="0"/>
                <participants group_id="P6" count="0"/>
                <participants group_id="P7" count="0"/>
                <participants group_id="P8" count="0"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="3"/>
                <participants group_id="P2" count="2"/>
                <participants group_id="P3" count="5"/>
                <participants group_id="P4" count="3"/>
                <participants group_id="P5" count="0"/>
                <participants group_id="P6" count="0"/>
                <participants group_id="P7" count="0"/>
                <participants group_id="P8" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Protocol-specified criteria</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="1"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="2"/>
                <participants group_id="P5" count="0"/>
                <participants group_id="P6" count="0"/>
                <participants group_id="P7" count="0"/>
                <participants group_id="P8" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Sponsor decision</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="1"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="0"/>
                <participants group_id="P6" count="0"/>
                <participants group_id="P7" count="0"/>
                <participants group_id="P8" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Withdrawal by Subject</title>
              <participants_list>
                <participants group_id="P1" count="2"/>
                <participants group_id="P2" count="1"/>
                <participants group_id="P3" count="4"/>
                <participants group_id="P4" count="1"/>
                <participants group_id="P5" count="0"/>
                <participants group_id="P6" count="0"/>
                <participants group_id="P7" count="0"/>
                <participants group_id="P8" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Subject missed week 24 assessment</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="0"/>
                <participants group_id="P6" count="0"/>
                <participants group_id="P7" count="0"/>
                <participants group_id="P8" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
        <period>
          <title>Open-Label Treatment Phase (OLTP)</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="386"/>
                <participants group_id="P6" count="73"/>
                <participants group_id="P7" count="0"/>
                <participants group_id="P8" count="0"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>Received Only 70 mg in OLTP</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="270"/>
                <participants group_id="P6" count="0"/>
                <participants group_id="P7" count="0"/>
                <participants group_id="P8" count="0"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>Received Only 140 mg in OLTP</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="0"/>
                <participants group_id="P6" count="73"/>
                <participants group_id="P7" count="0"/>
                <participants group_id="P8" count="0"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>Received Both 70 mg and 140 mg in OLTP</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="116"/>
                <participants group_id="P6" count="0"/>
                <participants group_id="P7" count="0"/>
                <participants group_id="P8" count="0"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="357"/>
                <participants group_id="P6" count="69"/>
                <participants group_id="P7" count="0"/>
                <participants group_id="P8" count="0"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="29"/>
                <participants group_id="P6" count="4"/>
                <participants group_id="P7" count="0"/>
                <participants group_id="P8" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Protocol-Specified Criteria</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="4"/>
                <participants group_id="P6" count="1"/>
                <participants group_id="P7" count="0"/>
                <participants group_id="P8" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Subject Request</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="24"/>
                <participants group_id="P6" count="3"/>
                <participants group_id="P7" count="0"/>
                <participants group_id="P8" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Decision by Sponsor</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="1"/>
                <participants group_id="P6" count="0"/>
                <participants group_id="P7" count="0"/>
                <participants group_id="P8" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
        <period>
          <title>Optional CHU Sub-Study (During OLTP)</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="0"/>
                <participants group_id="P6" count="0"/>
                <participants group_id="P7" count="24"/>
                <participants group_id="P8" count="25"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="0"/>
                <participants group_id="P6" count="0"/>
                <participants group_id="P7" count="24"/>
                <participants group_id="P8" count="25"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="0"/>
                <participants group_id="P6" count="0"/>
                <participants group_id="P7" count="0"/>
                <participants group_id="P8" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>DBTP: Placebo</title>
          <description>Placebo SC on day 1 and at weeks 4, 8, 12, 16, and 20 in the DBTP.</description>
        </group>
        <group group_id="B2">
          <title>DBTP: Erenumab 28 mg QM</title>
          <description>Erenumab 28 mg SC on day 1 and at weeks 4, 8, 12, 16, and 20 in the DBTP.</description>
        </group>
        <group group_id="B3">
          <title>DPTP: Erenumab 70 mg QM</title>
          <description>Erenumab 70 mg SC on day 1 and at weeks 4, 8, 12, 16, and 20 in the DBTP.</description>
        </group>
        <group group_id="B4">
          <title>DBTP: Erenumab 140 mg QM</title>
          <description>Erenumab 140 mg SC on day 1 and at weeks 4, 8, 12, 16, and 20 in the DBTP.</description>
        </group>
        <group group_id="B5">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="136"/>
            <count group_id="B2" value="67"/>
            <count group_id="B3" value="135"/>
            <count group_id="B4" value="137"/>
            <count group_id="B5" value="475"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>Years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="43.7" spread="9.1"/>
                    <measurement group_id="B2" value="42.8" spread="6.9"/>
                    <measurement group_id="B3" value="43.8" spread="9.0"/>
                    <measurement group_id="B4" value="45.0" spread="8.3"/>
                    <measurement group_id="B5" value="44.0" spread="8.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="118"/>
                    <measurement group_id="B2" value="55"/>
                    <measurement group_id="B3" value="115"/>
                    <measurement group_id="B4" value="112"/>
                    <measurement group_id="B5" value="400"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="18"/>
                    <measurement group_id="B2" value="12"/>
                    <measurement group_id="B3" value="20"/>
                    <measurement group_id="B4" value="25"/>
                    <measurement group_id="B5" value="75"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Ethnicity (NIH/OMB)</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Hispanic or Latino</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Not Hispanic or Latino</title>
                  <measurement_list>
                    <measurement group_id="B1" value="136"/>
                    <measurement group_id="B2" value="67"/>
                    <measurement group_id="B3" value="135"/>
                    <measurement group_id="B4" value="137"/>
                    <measurement group_id="B5" value="475"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Unknown or Not Reported</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race (NIH/OMB)</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>American Indian or Alaska Native</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Asian</title>
                  <measurement_list>
                    <measurement group_id="B1" value="136"/>
                    <measurement group_id="B2" value="67"/>
                    <measurement group_id="B3" value="135"/>
                    <measurement group_id="B4" value="137"/>
                    <measurement group_id="B5" value="475"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Native Hawaiian or Other Pacific Islander</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Black or African American</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>White</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>More than one race</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Unknown or Not Reported</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Monthly Migraine Days at Baseline</title>
          <description>The number of migraine days in the 4-week baseline period. A migraine day was defined as any calendar day in which the participant experienced a qualified migraine headache (onset, continuation or recurrence of the migraine headache). A qualified migraine headache was defined as a migraine with or without aura, lasting for ≥ 30 minutes and meeting at least one of the pre-specified pain features and/or associated symptoms criteria.</description>
          <units>Days</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="7.67" spread="2.34"/>
                    <measurement group_id="B2" value="7.68" spread="2.14"/>
                    <measurement group_id="B3" value="7.84" spread="2.31"/>
                    <measurement group_id="B4" value="8.14" spread="2.43"/>
                    <measurement group_id="B5" value="7.86" spread="2.33"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Treatment Status with Migraine Prophylactic Medication</title>
          <description>Treatment status values presented are those utilized in the randomization process.</description>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <title>Current treatment</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="14"/>
                    <measurement group_id="B2" value="7"/>
                    <measurement group_id="B3" value="13"/>
                    <measurement group_id="B4" value="15"/>
                    <measurement group_id="B5" value="49"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Prior treatment only</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="75"/>
                    <measurement group_id="B2" value="38"/>
                    <measurement group_id="B3" value="75"/>
                    <measurement group_id="B4" value="75"/>
                    <measurement group_id="B5" value="263"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>No prior or current treatment</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="47"/>
                    <measurement group_id="B2" value="22"/>
                    <measurement group_id="B3" value="47"/>
                    <measurement group_id="B4" value="47"/>
                    <measurement group_id="B5" value="163"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Change From Baseline in Mean Monthly Migraine Days at Months 4, 5 and 6</title>
        <description>A migraine day was defined as any calendar day in which the participant experienced a qualified migraine headache (onset, continuation or recurrence of the migraine headache). A qualified migraine headache was a migraine with or without aura, lasting for ≥ 30 minutes, and meeting at least one of the following criteria: a) ≥ 2 of the following pain features: unilateral, throbbing, moderate to severe, exacerbated with exercise/physical activity; b) ≥ 1 of the following associated symptoms: nausea and/or vomiting, photophobia and phonophobia. Change from baseline was calculated using the mean monthly migraine days from months 4, 5 and 6 of the DBTP minus the number of migraine days during the 4-week baseline phase. Least squares (LS) mean was estimated using a generalized linear mixed model which included treatment, visit, treatment by visit interaction, stratification factor (current, prior only, or no prior/current treatment), and baseline value as covariates.</description>
        <time_frame>4-week baseline phase and months 4, 5 and 6 of DBTP.</time_frame>
        <population>Efficacy Analysis Set: Participants who received at least 1 dose of the investigational product (IP) and had at least 1 change from baseline measurement in monthly migraine days during the DBTP.</population>
        <group_list>
          <group group_id="O1">
            <title>DBTP: Placebo</title>
            <description>Placebo SC on day 1 and at weeks 4, 8, 12, 16, and 20 in the DBTP.</description>
          </group>
          <group group_id="O2">
            <title>DBTP: Erenumab 28 mg QM</title>
            <description>Erenumab 28 mg SC on day 1 and at weeks 4, 8, 12, 16, and 20 in the DBTP.</description>
          </group>
          <group group_id="O3">
            <title>DPTP: Erenumab 70 mg QM</title>
            <description>Erenumab 70 mg SC on day 1 and at weeks 4, 8, 12, 16, and 20 in the DBTP.</description>
          </group>
          <group group_id="O4">
            <title>DBTP: Erenumab 140 mg QM</title>
            <description>Erenumab 140 mg SC on day 1 and at weeks 4, 8, 12, 16, and 20 in the DBTP.</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in Mean Monthly Migraine Days at Months 4, 5 and 6</title>
          <description>A migraine day was defined as any calendar day in which the participant experienced a qualified migraine headache (onset, continuation or recurrence of the migraine headache). A qualified migraine headache was a migraine with or without aura, lasting for ≥ 30 minutes, and meeting at least one of the following criteria: a) ≥ 2 of the following pain features: unilateral, throbbing, moderate to severe, exacerbated with exercise/physical activity; b) ≥ 1 of the following associated symptoms: nausea and/or vomiting, photophobia and phonophobia. Change from baseline was calculated using the mean monthly migraine days from months 4, 5 and 6 of the DBTP minus the number of migraine days during the 4-week baseline phase. Least squares (LS) mean was estimated using a generalized linear mixed model which included treatment, visit, treatment by visit interaction, stratification factor (current, prior only, or no prior/current treatment), and baseline value as covariates.</description>
          <population>Efficacy Analysis Set: Participants who received at least 1 dose of the investigational product (IP) and had at least 1 change from baseline measurement in monthly migraine days during the DBTP.</population>
          <units>Days</units>
          <param>Least Squares Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="136"/>
                <count group_id="O2" value="66"/>
                <count group_id="O3" value="135"/>
                <count group_id="O4" value="136"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.06" lower_limit="-0.46" upper_limit="0.58"/>
                    <measurement group_id="O2" value="-1.19" lower_limit="-1.91" upper_limit="-0.47"/>
                    <measurement group_id="O3" value="-2.25" lower_limit="-2.78" upper_limit="-1.73"/>
                    <measurement group_id="O4" value="-1.83" lower_limit="-2.35" upper_limit="-1.31"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <groups_desc>The primary analysis utilized a generalized linear mixed model which included treatment, visit, treatment by visit interaction, stratification factor (prior/current treatment with migraine prophylactic medication status), and baseline value as covariates and assumed a first-order autoregressive covariance structure</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <non_inferiority_desc>To maintain a family-wise type I error at 0.05, the pairwise comparisons were tested in a sequential testing procedure in the order of erenumab 140 mg QM vs placebo, erenumab 70 mg QM vs placebo and erenumab 28 mg QM vs placebo. The lower dose group was tested only when the higher dose group was considered statistically significant.</non_inferiority_desc>
            <p_value>&lt;0.001</p_value>
            <p_value_desc>P-values for pairwise comparisons were nominal and without multiplicity adjustment.</p_value_desc>
            <method>Generalized Linear Mixed Model</method>
            <param_type>LS Mean Difference</param_type>
            <param_value>-1.89</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-2.58</ci_lower_limit>
            <ci_upper_limit>-1.20</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>The primary analysis utilized a generalized linear mixed model which included treatment, visit, treatment by visit interaction, stratification factor (prior/current treatment with migraine prophylactic medication status), and baseline value as covariates and assumed a first-order autoregressive covariance structure</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <non_inferiority_desc>To maintain a family-wise type I error at 0.05, the pairwise comparisons were tested in a sequential testing procedure in the order of erenumab 140 mg QM vs placebo, erenumab 70 mg QM vs placebo and erenumab 28 mg QM vs placebo. The lower dose group was tested only when the higher dose group was considered statistically significant.</non_inferiority_desc>
            <p_value>&lt;0.001</p_value>
            <p_value_desc>P-values for pairwise comparisons were nominal and without multiplicity adjustment.</p_value_desc>
            <method>Generalized Linear Mixed Model</method>
            <param_type>LS Mean Difference</param_type>
            <param_value>-2.31</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-3.00</ci_lower_limit>
            <ci_upper_limit>-1.62</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>The primary analysis utilized a generalized linear mixed model which included treatment, visit, treatment by visit interaction, stratification factor (prior/current treatment with migraine prophylactic medication status), and baseline value as covariates and assumed a first-order autoregressive covariance structure</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <non_inferiority_desc>To maintain a family-wise type I error at 0.05, the pairwise comparisons were tested in a sequential testing procedure in the order of erenumab 140 mg QM vs placebo, erenumab 70 mg QM vs placebo and erenumab 28 mg QM vs placebo. The lower dose group was tested only when the higher dose group was considered statistically significant.</non_inferiority_desc>
            <p_value>0.004</p_value>
            <p_value_desc>P-values for pairwise comparisons were nominal and without multiplicity adjustment.</p_value_desc>
            <method>Generalized Linear Mixed Model</method>
            <param_type>LS Mean Difference</param_type>
            <param_value>-1.25</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-2.10</ci_lower_limit>
            <ci_upper_limit>-0.41</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>CHU Sub-Study: Participant-Reported Outcome of Attempted Full-Dose Administration at Day 29 (Week 4) and Day 57 (Week 8)</title>
        <description>On CHU day 29 and day 57, site staff interviewed sub-study participants and asked if they administered a full, partial, or no dose of erenumab (after explaining that a full dose means that the entire volume of the AI/pen was injected) and documented the participant's response in the electronic case report form. Data presented are the percentage of participants who reported &quot;full administration,&quot; &quot;not full administration,&quot; or &quot;discontinued investigational product (ie, no dose).&quot; (Day 1 of the CHU substudy occurred at any OLTP study visit [up to week 88] as long as the participant had previously received at least 1 OL dose of erenumab 140 mg.)</description>
        <time_frame>CHU day 29 (week 4) and day 57 (week 8)</time_frame>
        <population>CHU Sub-Study Analysis Set: all participants randomized into the CHU substudy who received at least one dose of CHU investigational product (IP).</population>
        <group_list>
          <group group_id="O1">
            <title>CHU Sub-Study: Two 70 mg/mL AI/Pens</title>
            <description>A subset of participants in the OLTP randomized to self-administer erenumab via two 70 mg/mL AI/pens on CHU sub-study day 1, day 29 and day 57.</description>
          </group>
          <group group_id="O2">
            <title>CHU Sub-Study: One 140 mg/mL AI/Pen</title>
            <description>A subset of participants in the OLTP randomized to self-administer erenumab via one 140 mg/mL AI/pen on CHU sub-study day 1, day 29 and day 57.</description>
          </group>
        </group_list>
        <measure>
          <title>CHU Sub-Study: Participant-Reported Outcome of Attempted Full-Dose Administration at Day 29 (Week 4) and Day 57 (Week 8)</title>
          <description>On CHU day 29 and day 57, site staff interviewed sub-study participants and asked if they administered a full, partial, or no dose of erenumab (after explaining that a full dose means that the entire volume of the AI/pen was injected) and documented the participant's response in the electronic case report form. Data presented are the percentage of participants who reported &quot;full administration,&quot; &quot;not full administration,&quot; or &quot;discontinued investigational product (ie, no dose).&quot; (Day 1 of the CHU substudy occurred at any OLTP study visit [up to week 88] as long as the participant had previously received at least 1 OL dose of erenumab 140 mg.)</description>
          <population>CHU Sub-Study Analysis Set: all participants randomized into the CHU substudy who received at least one dose of CHU investigational product (IP).</population>
          <units>percentage of participants</units>
          <param>Number</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="24"/>
                <count group_id="O2" value="25"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Week 4: Full Administration</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="100.0" lower_limit="86.2" upper_limit="100.0"/>
                    <measurement group_id="O2" value="100.0" lower_limit="86.7" upper_limit="100.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 4: Not Full Administration</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.0" lower_limit="0.0" upper_limit="13.8"/>
                    <measurement group_id="O2" value="0.0" lower_limit="0.0" upper_limit="13.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 4: Discontinued Investigational Product</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.0" lower_limit="0.0" upper_limit="13.8"/>
                    <measurement group_id="O2" value="0.0" lower_limit="0.0" upper_limit="13.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 8: Full Administration</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="100.0" lower_limit="86.2" upper_limit="100.0"/>
                    <measurement group_id="O2" value="100.0" lower_limit="86.7" upper_limit="100.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 8: Not Full Administration</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.0" lower_limit="0.0" upper_limit="13.8"/>
                    <measurement group_id="O2" value="0.0" lower_limit="0.0" upper_limit="13.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 8: Discontinued Investigational Product</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.0" lower_limit="0.0" upper_limit="13.8"/>
                    <measurement group_id="O2" value="0.0" lower_limit="0.0" upper_limit="13.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Week 4: Full Administration</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <param_type>Treatment Difference</param_type>
            <param_value>0.0</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-13.3</ci_lower_limit>
            <ci_upper_limit>13.8</ci_upper_limit>
            <estimate_desc>The 95% CI for the difference was calculated using the Newcombe hybrid score method.</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Week 4: Not Full Administration</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <param_type>Treatment Difference</param_type>
            <param_value>0.0</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-13.8</ci_lower_limit>
            <ci_upper_limit>13.3</ci_upper_limit>
            <estimate_desc>The 95% CI for the difference was calculated using the Newcombe hybrid score method.</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Week 4: Discontinued Investigational Product</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <param_type>Treatment Difference</param_type>
            <param_value>0.0</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-13.8</ci_lower_limit>
            <ci_upper_limit>13.3</ci_upper_limit>
            <estimate_desc>The 95% CI for the difference was calculated using the Newcombe hybrid score method.</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Week 8: Full Administration</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <param_type>Treatment Difference</param_type>
            <param_value>0.0</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-13.3</ci_lower_limit>
            <ci_upper_limit>13.8</ci_upper_limit>
            <estimate_desc>The 95% CI for the difference was calculated using the Newcombe hybrid score method.</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Week 8: Not Full Administration</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <param_type>Treatment Difference</param_type>
            <param_value>0.0</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-13.8</ci_lower_limit>
            <ci_upper_limit>13.3</ci_upper_limit>
            <estimate_desc>The 95% CI for the difference was calculated using the Newcombe hybrid score method.</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Week 8: Discontinued Investigational Product</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <param_type>Treatment Difference</param_type>
            <param_value>0.0</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-13.8</ci_lower_limit>
            <ci_upper_limit>13.3</ci_upper_limit>
            <estimate_desc>The 95% CI for the difference was calculated using the Newcombe hybrid score method.</estimate_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percentage of Participants With at Least a 50% Reduction From Baseline in Mean Monthly Migraine Days at Months 4, 5 and 6</title>
        <description>A migraine day was defined as any calendar day in which the participant experienced a qualified migraine headache (onset, continuation or recurrence of the migraine headache). A qualified migraine headache was a migraine with or without aura, lasting for ≥ 30 minutes, and meeting at least one of the following criteria: a) ≥ 2 of the following pain features: unilateral, throbbing, moderate to severe, exacerbated with exercise/physical activity; b) ≥ 1 of the following associated symptoms: nausea and/or vomiting, photophobia and phonophobia.&#xD;
At least a 50% reduction from baseline in monthly migraine days was determined if: (mean monthly migraine days over the last three months of the DBTP minus baseline monthly migraine days) * 100 / baseline monthly migraine days, was less than or equal to -50%.</description>
        <time_frame>4-week baseline phase and months 4, 5 and 6 of DBTP.</time_frame>
        <population>Efficacy Analysis Set: Participants who received at least 1 dose of IP and had at least 1 change from baseline measurement in monthly migraine days during the DBTP.</population>
        <group_list>
          <group group_id="O1">
            <title>DBTP: Placebo</title>
            <description>Placebo SC on day 1 and at weeks 4, 8, 12, 16, and 20 in the DBTP.</description>
          </group>
          <group group_id="O2">
            <title>DBTP: Erenumab 28 mg QM</title>
            <description>Erenumab 28 mg SC on day 1 and at weeks 4, 8, 12, 16, and 20 in the DBTP.</description>
          </group>
          <group group_id="O3">
            <title>DPTP: Erenumab 70 mg QM</title>
            <description>Erenumab 70 mg SC on day 1 and at weeks 4, 8, 12, 16, and 20 in the DBTP.</description>
          </group>
          <group group_id="O4">
            <title>DBTP: Erenumab 140 mg QM</title>
            <description>Erenumab 140 mg SC on day 1 and at weeks 4, 8, 12, 16, and 20 in the DBTP.</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Participants With at Least a 50% Reduction From Baseline in Mean Monthly Migraine Days at Months 4, 5 and 6</title>
          <description>A migraine day was defined as any calendar day in which the participant experienced a qualified migraine headache (onset, continuation or recurrence of the migraine headache). A qualified migraine headache was a migraine with or without aura, lasting for ≥ 30 minutes, and meeting at least one of the following criteria: a) ≥ 2 of the following pain features: unilateral, throbbing, moderate to severe, exacerbated with exercise/physical activity; b) ≥ 1 of the following associated symptoms: nausea and/or vomiting, photophobia and phonophobia.&#xD;
At least a 50% reduction from baseline in monthly migraine days was determined if: (mean monthly migraine days over the last three months of the DBTP minus baseline monthly migraine days) * 100 / baseline monthly migraine days, was less than or equal to -50%.</description>
          <population>Efficacy Analysis Set: Participants who received at least 1 dose of IP and had at least 1 change from baseline measurement in monthly migraine days during the DBTP.</population>
          <units>Percentage of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="136"/>
                <count group_id="O2" value="66"/>
                <count group_id="O3" value="135"/>
                <count group_id="O4" value="136"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="7.4"/>
                    <measurement group_id="O2" value="19.7"/>
                    <measurement group_id="O3" value="28.9"/>
                    <measurement group_id="O4" value="27.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <groups_desc>The common odds ratios and p-values were obtained from a Cochran-Mantel-Haenszel (CMH) test, stratified by stratification factor prior/current treatment with migraine prophylactic medication status.</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <p_value_desc>P-values for pairwise comparisons were nominal and obtained from the CMH test using data including placebo and corresponding erenumab dose group only.</p_value_desc>
            <method>Cochran-Mantel-Haenszel</method>
            <param_type>Common Odds Ratio</param_type>
            <param_value>4.73</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>2.24</ci_lower_limit>
            <ci_upper_limit>9.99</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>The common odds ratios and p-values were obtained from a CMH test, stratified by stratification factor prior/current treatment with migraine prophylactic medication status.</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <p_value_desc>P-values for pairwise comparisons were nominal and obtained from the CMH test using data including placebo and corresponding erenumab dose group only.</p_value_desc>
            <method>Cochran-Mantel-Haenszel</method>
            <param_type>Common Odds Ratio</param_type>
            <param_value>5.60</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>2.60</ci_lower_limit>
            <ci_upper_limit>12.06</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>The common odds ratios and p-values were obtained from a CMH test, stratified by stratification factor prior/current treatment with migraine prophylactic medication status.</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.009</p_value>
            <p_value_desc>P-values for pairwise comparisons were nominal and obtained from the CMH test using data including placebo and corresponding erenumab dose group only.</p_value_desc>
            <method>Cochran-Mantel-Haenszel</method>
            <param_type>Common Odds Ratio</param_type>
            <param_value>3.21</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>1.30</ci_lower_limit>
            <ci_upper_limit>7.88</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline in Mean Monthly Acute Migraine-Specific Medication Treatment Days at Months 4, 5 and 6</title>
        <description>An acute migraine-specific medication treatment day was defined as any calendar day during which the participant took a migraine-specific medication (ie, triptan or ergotamine-derivatives).&#xD;
The change from baseline was calculated using the mean monthly acute migraine-specific medication treatment days over the last three months (months 4, 5 and 6) of the DBTP minus the baseline monthly acute migraine-specific medication treatment days.&#xD;
LS mean was estimated using a generalized linear mixed model which included treatment, visit, treatment by visit interaction, stratification factor (prior/current treatment), and baseline value as covariates.</description>
        <time_frame>4-week baseline phase and months 4, 5 and 6 of DBTP.</time_frame>
        <population>Efficacy Analysis Set: Participants who received at least 1 dose of IP and had at least 1 change from baseline measurement in monthly migraine days during the DBTP.</population>
        <group_list>
          <group group_id="O1">
            <title>DBTP: Placebo</title>
            <description>Placebo SC on day 1 and at weeks 4, 8, 12, 16, and 20 in the DBTP.</description>
          </group>
          <group group_id="O2">
            <title>DBTP: Erenumab 28 mg QM</title>
            <description>Erenumab 28 mg SC on day 1 and at weeks 4, 8, 12, 16, and 20 in the DBTP.</description>
          </group>
          <group group_id="O3">
            <title>DPTP: Erenumab 70 mg QM</title>
            <description>Erenumab 70 mg SC on day 1 and at weeks 4, 8, 12, 16, and 20 in the DBTP.</description>
          </group>
          <group group_id="O4">
            <title>DBTP: Erenumab 140 mg QM</title>
            <description>Erenumab 140 mg SC on day 1 and at weeks 4, 8, 12, 16, and 20 in the DBTP.</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in Mean Monthly Acute Migraine-Specific Medication Treatment Days at Months 4, 5 and 6</title>
          <description>An acute migraine-specific medication treatment day was defined as any calendar day during which the participant took a migraine-specific medication (ie, triptan or ergotamine-derivatives).&#xD;
The change from baseline was calculated using the mean monthly acute migraine-specific medication treatment days over the last three months (months 4, 5 and 6) of the DBTP minus the baseline monthly acute migraine-specific medication treatment days.&#xD;
LS mean was estimated using a generalized linear mixed model which included treatment, visit, treatment by visit interaction, stratification factor (prior/current treatment), and baseline value as covariates.</description>
          <population>Efficacy Analysis Set: Participants who received at least 1 dose of IP and had at least 1 change from baseline measurement in monthly migraine days during the DBTP.</population>
          <units>Days</units>
          <param>Least Squares Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="136"/>
                <count group_id="O2" value="66"/>
                <count group_id="O3" value="135"/>
                <count group_id="O4" value="136"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.88" lower_limit="0.44" upper_limit="1.33"/>
                    <measurement group_id="O2" value="-0.19" lower_limit="-0.80" upper_limit="0.43"/>
                    <measurement group_id="O3" value="-1.19" lower_limit="-1.64" upper_limit="-0.74"/>
                    <measurement group_id="O4" value="-1.16" lower_limit="-1.60" upper_limit="-0.71"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <groups_desc>The primary analysis utilized a generalized linear mixed model which included treatment, visit, treatment by visit interaction, stratification factor (prior/current treatment with migraine prophylactic medication status), and baseline value as covariates and assumed a first-order autoregressive covariance structure</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <non_inferiority_desc>To maintain a family-wise type I error at 0.05, the pairwise comparisons were tested in a sequential testing procedure in the order of erenumab 140 mg QM vs placebo, erenumab 70 mg QM vs placebo and erenumab 28 mg QM vs placebo. The lower dose group was tested only when the higher dose group was considered statistically significant.</non_inferiority_desc>
            <p_value>&lt;0.001</p_value>
            <p_value_desc>P-values for pairwise comparisons were nominal and without multiplicity adjustment.</p_value_desc>
            <method>Generalized Linear Mixed Model</method>
            <param_type>LS Mean Difference</param_type>
            <param_value>-2.04</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-2.63</ci_lower_limit>
            <ci_upper_limit>-1.45</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>The primary analysis utilized a generalized linear mixed model which included treatment, visit, treatment by visit interaction, stratification factor (prior/current treatment with migraine prophylactic medication status), and baseline value as covariates and assumed a first-order autoregressive covariance structure</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <non_inferiority_desc>To maintain a family-wise type I error at 0.05, the pairwise comparisons were tested in a sequential testing procedure in the order of erenumab 140 mg QM vs placebo, erenumab 70 mg QM vs placebo and erenumab 28 mg QM vs placebo. The lower dose group was tested only when the higher dose group was considered statistically significant.</non_inferiority_desc>
            <p_value>&lt;0.001</p_value>
            <p_value_desc>P-values for pairwise comparisons were nominal and without multiplicity adjustment.</p_value_desc>
            <method>Generalized Linear Mixed Model</method>
            <param_type>LS Mean Difference</param_type>
            <param_value>-2.07</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-2.66</ci_lower_limit>
            <ci_upper_limit>-1.49</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>The primary analysis utilized a generalized linear mixed model which included treatment, visit, treatment by visit interaction, stratification factor (prior/current treatment with migraine prophylactic medication status), and baseline value as covariates and assumed a first-order autoregressive covariance structure</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <non_inferiority_desc>To maintain a family-wise type I error at 0.05, the pairwise comparisons were tested in a sequential testing procedure in the order of erenumab 140 mg QM vs placebo, erenumab 70 mg QM vs placebo and erenumab 28 mg QM vs placebo. The lower dose group was tested only when the higher dose group was considered statistically significant.</non_inferiority_desc>
            <p_value>0.004</p_value>
            <p_value_desc>P-values for pairwise comparisons were nominal and without multiplicity adjustment.</p_value_desc>
            <method>Generalized Linear Mixed Model</method>
            <param_type>LS Mean Difference</param_type>
            <param_value>-1.07</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-1.80</ci_lower_limit>
            <ci_upper_limit>-0.35</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Participants With Treatment Emergent Adverse Events (TEAEs), Serious TEAEs, Discontinuations Due to TEAEs, and Fatal TEAEs During the DBTP</title>
        <description>An adverse event (AE) is defined as any untoward medical occurrence in a clinical trial participant. A serious adverse event (SAE) is defined as an adverse event that meets at least 1 of the following serious criteria: fatal; life threatening; requires in-patient hospitalization or prolongation of existing hospitalization; results in persistent or significant disability/incapacity; congenital anomaly/birth defect; other medically important serious event. Events were graded according to the National Cancer Institute Common Terminology Criteria for Adverse Events (NCI CTCAE) version 4.03 (grade 1=mild, grade 2=moderate, grade 3=severe, grade 4= life-threatening, grade 5=death).</description>
        <time_frame>From first dose of IP up to week 24</time_frame>
        <population>Safety Analysis Set: all randomized participants who received at least one dose of IP in the DBTP.</population>
        <group_list>
          <group group_id="O1">
            <title>DBTP: Placebo</title>
            <description>Placebo SC on day 1 and at weeks 4, 8, 12, 16, and 20 in the DBTP.</description>
          </group>
          <group group_id="O2">
            <title>DBTP: Erenumab 28 mg QM</title>
            <description>Erenumab 28 mg SC on day 1 and at weeks 4, 8, 12, 16, and 20 in the DBTP.</description>
          </group>
          <group group_id="O3">
            <title>DPTP: Erenumab 70 mg QM</title>
            <description>Erenumab 70 mg SC on day 1 and at weeks 4, 8, 12, 16, and 20 in the DBTP.</description>
          </group>
          <group group_id="O4">
            <title>DBTP: Erenumab 140 mg QM</title>
            <description>Erenumab 140 mg SC on day 1 and at weeks 4, 8, 12, 16, and 20 in the DBTP.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With Treatment Emergent Adverse Events (TEAEs), Serious TEAEs, Discontinuations Due to TEAEs, and Fatal TEAEs During the DBTP</title>
          <description>An adverse event (AE) is defined as any untoward medical occurrence in a clinical trial participant. A serious adverse event (SAE) is defined as an adverse event that meets at least 1 of the following serious criteria: fatal; life threatening; requires in-patient hospitalization or prolongation of existing hospitalization; results in persistent or significant disability/incapacity; congenital anomaly/birth defect; other medically important serious event. Events were graded according to the National Cancer Institute Common Terminology Criteria for Adverse Events (NCI CTCAE) version 4.03 (grade 1=mild, grade 2=moderate, grade 3=severe, grade 4= life-threatening, grade 5=death).</description>
          <population>Safety Analysis Set: all randomized participants who received at least one dose of IP in the DBTP.</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="136"/>
                <count group_id="O2" value="66"/>
                <count group_id="O3" value="135"/>
                <count group_id="O4" value="137"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>All TEAEs</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="92"/>
                    <measurement group_id="O2" value="40"/>
                    <measurement group_id="O3" value="95"/>
                    <measurement group_id="O4" value="95"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Grade ≥ 2 TEAEs</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="60"/>
                    <measurement group_id="O2" value="33"/>
                    <measurement group_id="O3" value="66"/>
                    <measurement group_id="O4" value="65"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Grade ≥ 3 TEAEs</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4"/>
                    <measurement group_id="O2" value="1"/>
                    <measurement group_id="O3" value="3"/>
                    <measurement group_id="O4" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Grade ≥ 4 TEAEs</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="1"/>
                    <measurement group_id="O4" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Serious TEAEs</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4"/>
                    <measurement group_id="O2" value="1"/>
                    <measurement group_id="O3" value="1"/>
                    <measurement group_id="O4" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>TEAEs Leading to Discontinuation of IP</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="2"/>
                    <measurement group_id="O4" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Fatal TEAEs</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Participants With TEAEs, Serious TEAEs, Discontinuations Due to TEAEs, and Fatal TEAEs During the OLTP</title>
        <description>An AE is defined as any untoward medical occurrence in a clinical trial participant. An SAE is defined as an adverse event that meets at least 1 of the following serious criteria: fatal; life threatening; requires in-patient hospitalization or prolongation of existing hospitalization; results in persistent or significant disability/incapacity; congenital anomaly/birth defect; other medically important serious event. Events were graded according to the NCI CTCAE version 4.03 (grade 1=mild, grade 2=moderate, grade 3=severe, grade 4= life-threatening, grade 5=death).</description>
        <time_frame>From first dose of IP in the OLTP (week 24) through the end of the OLTP (week 100) plus 12 weeks</time_frame>
        <population>Open-Label Treatment Phase Set: all participants receiving at least one dose of IP in the OLTP, by dose received at the time of the event, and overall (total participants in the OLTP).</population>
        <group_list>
          <group group_id="O1">
            <title>OLTP: Erenumab 70 mg QM</title>
            <description>Erenumab 70 mg SC QM in the OLTP (at the time of the event).</description>
          </group>
          <group group_id="O2">
            <title>OLTP: Erenumab 140 mg QM</title>
            <description>Erenumab 140 mg SC QM in the OLTP (at the time of the event).</description>
          </group>
          <group group_id="O3">
            <title>OLTP: Total</title>
            <description>Participants receiving erenumab 70 mg and/or 140 mg SC QM in the OLTP</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With TEAEs, Serious TEAEs, Discontinuations Due to TEAEs, and Fatal TEAEs During the OLTP</title>
          <description>An AE is defined as any untoward medical occurrence in a clinical trial participant. An SAE is defined as an adverse event that meets at least 1 of the following serious criteria: fatal; life threatening; requires in-patient hospitalization or prolongation of existing hospitalization; results in persistent or significant disability/incapacity; congenital anomaly/birth defect; other medically important serious event. Events were graded according to the NCI CTCAE version 4.03 (grade 1=mild, grade 2=moderate, grade 3=severe, grade 4= life-threatening, grade 5=death).</description>
          <population>Open-Label Treatment Phase Set: all participants receiving at least one dose of IP in the OLTP, by dose received at the time of the event, and overall (total participants in the OLTP).</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="386"/>
                <count group_id="O2" value="189"/>
                <count group_id="O3" value="459"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>All TEAEs</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="292"/>
                    <measurement group_id="O2" value="173"/>
                    <measurement group_id="O3" value="422"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Grade ≥ 2 TEAEs</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="238"/>
                    <measurement group_id="O2" value="147"/>
                    <measurement group_id="O3" value="358"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Grade ≥ 3 TEAEs</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="19"/>
                    <measurement group_id="O2" value="9"/>
                    <measurement group_id="O3" value="28"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Grade ≥ 4 TEAEs</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Serious TEAEs</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="18"/>
                    <measurement group_id="O2" value="9"/>
                    <measurement group_id="O3" value="27"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>TEAEs Leading to Discontinuation of IP</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4"/>
                    <measurement group_id="O2" value="2"/>
                    <measurement group_id="O3" value="6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Fatal TEAEs</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Participants With TEAEs, Serious TEAEs, Discotninuations Due to TEAEs, Fatal TEAEs, and Adverse Device Effects During the CHU Sub-Study</title>
        <description>An AE is defined as any untoward medical occurrence in a clinical trial participant. An SAE is defined as an adverse event that meets at least 1 of the following serious criteria: fatal; life threatening; requires in-patient hospitalization or prolongation of existing hospitalization; results in persistent or significant disability/incapacity; congenital anomaly/birth defect; other medically important serious event. Events were graded according to the NCI CTCAE version 4.03 (grade 1=mild, grade 2=moderate, grade 3=severe, grade 4= life-threatening, grade 5=death). TEAEs leading to discontinuation of IP are TEAEs leading to complete discontinuation of erenumab regardless of CHU IP or parent study IP.</description>
        <time_frame>CHU sub-study day 1 through day 85 (end of CHU sub-study). Day 1 of the CHU substudy occurred at any OLTP study visit (up to week 88) as long as the participant had previously received at least 1 OL dose of erenumab 140 mg.</time_frame>
        <population>CHU Sub-Study Analysis Set: all participants randomized into the CHU substudy who received at least one dose of CHU IP.</population>
        <group_list>
          <group group_id="O1">
            <title>CHU Sub-Study: Two 70 mg/mL AI/Pens</title>
            <description>A subset of participants in the OLTP randomized to self-administer erenumab via two 70 mg/mL AI/pens on CHU sub-study day 1, day 29 and day 57.</description>
          </group>
          <group group_id="O2">
            <title>CHU Sub-Study: One 140 mg/mL AI/Pen</title>
            <description>A subset of participants in the OLTP randomized to self-administer erenumab via one 140 mg/mL AI/pen on CHU sub-study day 1, day 29 and day 57.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With TEAEs, Serious TEAEs, Discotninuations Due to TEAEs, Fatal TEAEs, and Adverse Device Effects During the CHU Sub-Study</title>
          <description>An AE is defined as any untoward medical occurrence in a clinical trial participant. An SAE is defined as an adverse event that meets at least 1 of the following serious criteria: fatal; life threatening; requires in-patient hospitalization or prolongation of existing hospitalization; results in persistent or significant disability/incapacity; congenital anomaly/birth defect; other medically important serious event. Events were graded according to the NCI CTCAE version 4.03 (grade 1=mild, grade 2=moderate, grade 3=severe, grade 4= life-threatening, grade 5=death). TEAEs leading to discontinuation of IP are TEAEs leading to complete discontinuation of erenumab regardless of CHU IP or parent study IP.</description>
          <population>CHU Sub-Study Analysis Set: all participants randomized into the CHU substudy who received at least one dose of CHU IP.</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="24"/>
                <count group_id="O2" value="25"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>All TEAEs</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="11"/>
                    <measurement group_id="O2" value="14"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Grade ≥ 2 TEAEs</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="9"/>
                    <measurement group_id="O2" value="9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Grade ≥ 3 TEAEs</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Grade ≥ 4 TEAEs</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Serious TEAEs</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>TEAEs Leading to Discontinuation of IP</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Fatal TEAEs</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Adverse Device Effects</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2"/>
                    <measurement group_id="O2" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Participants With Post-Baseline Liver Function Test Abnormalities During the DBTP</title>
        <description>Post-baseline is defined as any assessment done after the first dose of IP. Liver Function tests included alkaline phosphatase (ALP), alanine aminotransferase (ALT), aspartate aminotransferase (AST), and total bilirubin (TBL). ULN=upper limit of normal.</description>
        <time_frame>From the first dose of study IP through the end of the DBTP (up to week 24)</time_frame>
        <population>Safety Analysis Set: all randomized participants who received at least one dose of IP.</population>
        <group_list>
          <group group_id="O1">
            <title>DBTP: Placebo</title>
            <description>Placebo SC on day 1 and at weeks 4, 8, 12, 16, and 20 in the DBTP.</description>
          </group>
          <group group_id="O2">
            <title>DBTP: Erenumab 28 mg QM</title>
            <description>Erenumab 28 mg SC on day 1 and at weeks 4, 8, 12, 16, and 20 in the DBTP.</description>
          </group>
          <group group_id="O3">
            <title>DPTP: Erenumab 70 mg QM</title>
            <description>Erenumab 70 mg SC on day 1 and at weeks 4, 8, 12, 16, and 20 in the DBTP.</description>
          </group>
          <group group_id="O4">
            <title>DBTP: Erenumab 140 mg QM</title>
            <description>Erenumab 140 mg SC on day 1 and at weeks 4, 8, 12, 16, and 20 in the DBTP.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With Post-Baseline Liver Function Test Abnormalities During the DBTP</title>
          <description>Post-baseline is defined as any assessment done after the first dose of IP. Liver Function tests included alkaline phosphatase (ALP), alanine aminotransferase (ALT), aspartate aminotransferase (AST), and total bilirubin (TBL). ULN=upper limit of normal.</description>
          <population>Safety Analysis Set: all randomized participants who received at least one dose of IP.</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="136"/>
                <count group_id="O2" value="66"/>
                <count group_id="O3" value="135"/>
                <count group_id="O4" value="137"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Post-Baseline ALT or AST &gt; 3 x ULN</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="3"/>
                    <measurement group_id="O4" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Post-Baseline ALT or AST &gt; 5 x ULN</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Post-Baseline TBL &gt; 1 x ULN</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="6"/>
                    <measurement group_id="O2" value="3"/>
                    <measurement group_id="O3" value="4"/>
                    <measurement group_id="O4" value="4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Post-Baseline TBL &gt; 1.5 x ULN</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="1"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Post-Baseline TBL &gt; 2 x ULN</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Post-Baseline ALP &gt; 1.5 x ULN</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Participants With Post-Baseline Liver Function Test Abnormalities During the OLTP</title>
        <description>Post-baseline is defined as any assessment done after the first dose of OLTP IP. Liver Function tests included alkaline phosphatase (ALP), alanine aminotransferase (ALT), aspartate aminotransferase (AST), and total bilirubin (TBL). ULN=upper limit of normal.</description>
        <time_frame>From the first dose of OLTP IP (week 24) through the end of the OLTP (up to week 100)</time_frame>
        <population>Safety Analysis Set: all randomized participants who received at least one dose of OLTP erenumab.</population>
        <group_list>
          <group group_id="O1">
            <title>OLTP: 70 mg SC QM (Only)</title>
            <description>Participants who received only erenumab 70 mg SC QM in the OLTP</description>
          </group>
          <group group_id="O2">
            <title>OLTP: 140 mg SC QM (Only)</title>
            <description>Participants who received only erenumab 140 mg SC QM in the OLTP</description>
          </group>
          <group group_id="O3">
            <title>OLTP: 70/140 mg SC QM (Both)</title>
            <description>Participants who received both erenumab 70 mg and 140 mg SC QM in the OLTP</description>
          </group>
          <group group_id="O4">
            <title>OLTP: Total</title>
            <description>Participants who received erenumab 70 mg and/or 140 mg SC QM in the OLTP</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With Post-Baseline Liver Function Test Abnormalities During the OLTP</title>
          <description>Post-baseline is defined as any assessment done after the first dose of OLTP IP. Liver Function tests included alkaline phosphatase (ALP), alanine aminotransferase (ALT), aspartate aminotransferase (AST), and total bilirubin (TBL). ULN=upper limit of normal.</description>
          <population>Safety Analysis Set: all randomized participants who received at least one dose of OLTP erenumab.</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="270"/>
                <count group_id="O2" value="73"/>
                <count group_id="O3" value="116"/>
                <count group_id="O4" value="459"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Post-Baseline ALT or AST &gt; 3 x ULN</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4"/>
                    <measurement group_id="O2" value="2"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Post-Baseline ALT or AST &gt; 5 x ULN</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Post-Baseline TBL &gt; 1 x ULN</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="12"/>
                    <measurement group_id="O2" value="3"/>
                    <measurement group_id="O3" value="6"/>
                    <measurement group_id="O4" value="21"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Post-Baseline TBL &gt; 1.5 x ULN</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Post-Baseline TBL &gt; 2 x ULN</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Post-Baseline ALP &gt; 1.5 x ULN</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Participants With Blood Pressure Changes From Baseline in Categories at Week 24 During the DBTP</title>
        <description>Participants with increases (↑) from baseline (BL) in diastolic blood pressure (DBP) and systolic blood pressure (SBP) at week 24 (Wk24) are presented.</description>
        <time_frame>Baseline (last assessment prior to first dose of IP), week 24</time_frame>
        <population>Safety Analysis Set: all randomized participants who received at least one dose of IP. Participants with an assessment at week 24.</population>
        <group_list>
          <group group_id="O1">
            <title>DBTP: Placebo</title>
            <description>Placebo SC on day 1 and at weeks 4, 8, 12, 16, and 20 in the DBTP.</description>
          </group>
          <group group_id="O2">
            <title>DBTP: Erenumab 28 mg QM</title>
            <description>Erenumab 28 mg SC on day 1 and at weeks 4, 8, 12, 16, and 20 in the DBTP.</description>
          </group>
          <group group_id="O3">
            <title>DPTP: Erenumab 70 mg QM</title>
            <description>Erenumab 70 mg SC on day 1 and at weeks 4, 8, 12, 16, and 20 in the DBTP.</description>
          </group>
          <group group_id="O4">
            <title>DBTP: Erenumab 140 mg QM</title>
            <description>Erenumab 140 mg SC on day 1 and at weeks 4, 8, 12, 16, and 20 in the DBTP.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With Blood Pressure Changes From Baseline in Categories at Week 24 During the DBTP</title>
          <description>Participants with increases (↑) from baseline (BL) in diastolic blood pressure (DBP) and systolic blood pressure (SBP) at week 24 (Wk24) are presented.</description>
          <population>Safety Analysis Set: all randomized participants who received at least one dose of IP. Participants with an assessment at week 24.</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="135"/>
                <count group_id="O2" value="65"/>
                <count group_id="O3" value="130"/>
                <count group_id="O4" value="134"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>↑ from BL ≥10 mmHg in DBP w/DBP &gt;90 mmHg at Wk24</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3"/>
                    <measurement group_id="O2" value="2"/>
                    <measurement group_id="O3" value="1"/>
                    <measurement group_id="O4" value="3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>↑ from BL ≥10 mmHg in DBP w/DBP ≤90 mmHg at Wk24</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="14"/>
                    <measurement group_id="O2" value="6"/>
                    <measurement group_id="O3" value="14"/>
                    <measurement group_id="O4" value="8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>↑ from BL ≥20 mmHg in SBP w/SBP &gt;140 mmHg at Wk24</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="1"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>↑ from BL ≥20 mmHg in SBP w/SBP ≤140 mmHg at Wk24</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="2"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Participants With Blood Pressure Changes From Pre-OLTP Baseline in Categories at Week 100 During the OLTP</title>
        <description>Participants with increases (↑) from baseline (BL) in diastolic blood pressure (DBP) and systolic blood pressure (SBP) at week 100 (Wk100) are presented.</description>
        <time_frame>Pre-OLTP Baseline (last assessment prior to first dose of IP in OLTP), week 100</time_frame>
        <population>Safety Analysis Set: all randomized participants who received at least one dose of IP in the OLTP. Participants with an assessment at week 100.</population>
        <group_list>
          <group group_id="O1">
            <title>OLTP: 70 mg SC QM (Only)</title>
            <description>Participants who received only erenumab 70 mg SC QM in the OLTP</description>
          </group>
          <group group_id="O2">
            <title>OLTP: 140 mg SC QM (Only)</title>
            <description>Participants who received only erenumab 140 mg SC QM in the OLTP</description>
          </group>
          <group group_id="O3">
            <title>OLTP: 70/140 mg SC QM (Both)</title>
            <description>Participants who received both erenumab 70 mg and 140 mg SC QM in the OLTP</description>
          </group>
          <group group_id="O4">
            <title>OLTP: Total</title>
            <description>Participants who received erenumab 70 mg and/or 140 mg SC QM in the OLTP</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With Blood Pressure Changes From Pre-OLTP Baseline in Categories at Week 100 During the OLTP</title>
          <description>Participants with increases (↑) from baseline (BL) in diastolic blood pressure (DBP) and systolic blood pressure (SBP) at week 100 (Wk100) are presented.</description>
          <population>Safety Analysis Set: all randomized participants who received at least one dose of IP in the OLTP. Participants with an assessment at week 100.</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="245"/>
                <count group_id="O2" value="68"/>
                <count group_id="O3" value="112"/>
                <count group_id="O4" value="425"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>↑ from BL ≥10 mmHg in DBP w/DBP &gt;90 mmHg at Wk100</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="8"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="2"/>
                    <measurement group_id="O4" value="10"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>↑ from BL ≥10 mmHg in DBP w/DBP ≤90 mmHg at Wk100</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="25"/>
                    <measurement group_id="O2" value="10"/>
                    <measurement group_id="O3" value="10"/>
                    <measurement group_id="O4" value="45"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>↑ from BL ≥20 mmHg in SBP w/SBP &gt;140 mmHg at Wk100</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="1"/>
                    <measurement group_id="O4" value="5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>↑ from BL ≥20 mmHg in SBP w/SBP ≤140 mmHg at Wk100</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="7"/>
                    <measurement group_id="O2" value="2"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Participants With Anti-Erenumab Antibodies During the Entire Study for Participants Who Received ≥ 1 Dose of Erenumab</title>
        <description>Data are summarized by the treatment participants received during the double-blind treatment phase. Placebo participants may have received erenumab 70 mg or 140 mg during the OLTP. Baseline is defined as the last antibody assessment on or prior to the first dose of erenumab.&#xD;
Transient binding/neutralizing antibody responses are defined as a negative (neg) result at the participant's last timepoint tested among participants who developed binding/neutralizing antibodies post-baseline.</description>
        <time_frame>Baseline (first dose of erenumab) up to end of study (week 100) plus 12 weeks</time_frame>
        <population>Safety Analysis Set: all randomized participants who received at least one dose of IP. Participants who received at least one dose of erenumab (during the DBTP and/or OLTP).</population>
        <group_list>
          <group group_id="O1">
            <title>DBTP: Placebo</title>
            <description>Placebo SC on day 1 and at weeks 4, 8, 12, 16, and 20 in the DBTP.</description>
          </group>
          <group group_id="O2">
            <title>DBTP: Erenumab 28 mg QM</title>
            <description>Erenumab 28 mg SC on day 1 and at weeks 4, 8, 12, 16, and 20 in the DBTP.</description>
          </group>
          <group group_id="O3">
            <title>DPTP: Erenumab 70 mg QM</title>
            <description>Erenumab 70 mg SC on day 1 and at weeks 4, 8, 12, 16, and 20 in the DBTP.</description>
          </group>
          <group group_id="O4">
            <title>DBTP: Erenumab 140 mg QM</title>
            <description>Erenumab 140 mg SC on day 1 and at weeks 4, 8, 12, 16, and 20 in the DBTP.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With Anti-Erenumab Antibodies During the Entire Study for Participants Who Received ≥ 1 Dose of Erenumab</title>
          <description>Data are summarized by the treatment participants received during the double-blind treatment phase. Placebo participants may have received erenumab 70 mg or 140 mg during the OLTP. Baseline is defined as the last antibody assessment on or prior to the first dose of erenumab.&#xD;
Transient binding/neutralizing antibody responses are defined as a negative (neg) result at the participant's last timepoint tested among participants who developed binding/neutralizing antibodies post-baseline.</description>
          <population>Safety Analysis Set: all randomized participants who received at least one dose of IP. Participants who received at least one dose of erenumab (during the DBTP and/or OLTP).</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="133"/>
                <count group_id="O2" value="66"/>
                <count group_id="O3" value="135"/>
                <count group_id="O4" value="137"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Binding Antibody Positive (BAb+) at Baseline (BL)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Neutralizing Antibody Positive (NAb+) at BL</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>BAb+ Post-BL With a Neg/No Result at BL</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4"/>
                    <measurement group_id="O2" value="5"/>
                    <measurement group_id="O3" value="6"/>
                    <measurement group_id="O4" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Transient BAb+ Post-BL With a Neg/No Result at BL</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2"/>
                    <measurement group_id="O2" value="4"/>
                    <measurement group_id="O3" value="5"/>
                    <measurement group_id="O4" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>NAb+ Post-BL With a Neg/No Result at BL</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Transient NAb+ Post-BL With a Neg/No Result at BL</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>All-cause mortality: from randomization through the end of study (up to 116 weeks). Treatment-emergent serious and non-serious events: - DBTP: from first dose of IP up to week 24 (end of DBTP) - OLTP: from first dose of OL IP (week 24) up to week 100 (end of OLTP) plus 12 weeks - CHU sub-study: from first dose of sub-study IP up to day 85 (end of sub-study)</time_frame>
      <desc>All-cause mortality is reported for all participants enrolled/randomized in the study. Serious adverse events and other adverse events are reported for all participants who received at least one dose of study drug.</desc>
      <group_list>
        <group group_id="E1">
          <title>DBTP: Placebo</title>
          <description>Placebo SC on day 1 and at weeks 4, 8, 12, 16, and 20 in the DBTP.</description>
        </group>
        <group group_id="E2">
          <title>DBTP: Erenumab 28 mg QM</title>
          <description>Erenumab 28 mg SC on day 1 and at weeks 4, 8, 12, 16, and 20 in the DBTP.</description>
        </group>
        <group group_id="E3">
          <title>DPTP: Erenumab 70 mg QM</title>
          <description>Erenumab 70 mg SC on day 1 and at weeks 4, 8, 12, 16, and 20 in the DBTP.</description>
        </group>
        <group group_id="E4">
          <title>DBTP: Erenumab 140 mg QM</title>
          <description>Erenumab 140 mg SC on day 1 and at weeks 4, 8, 12, 16, and 20 in the DBTP.</description>
        </group>
        <group group_id="E5">
          <title>OLTP: Erenumab 70 mg QM</title>
          <description>Erenumab 70 mg SC QM in the OLTP (at the time of the event).</description>
        </group>
        <group group_id="E6">
          <title>OLTP: Erenumab 140 mg QM</title>
          <description>Erenumab 140 mg SC QM in the OLTP (at the time of the event).</description>
        </group>
        <group group_id="E7">
          <title>OLTP Total: Erenumab 70/140 mg QM</title>
          <description>Erenumab 70 mg and/or 140 mg SC QM in the OLTP.</description>
        </group>
        <group group_id="E8">
          <title>CHU Sub-Study: Two Erenumab 70 mg/mL AI/Pens</title>
          <description>Self-administered erenumab via two 70 mg/mL AI/pens on day 1, day 29 and day 57 of the CHU sub-study.</description>
        </group>
        <group group_id="E9">
          <title>CHU Sub-Study: One Erenumab 140 mg/mL AI/Pen</title>
          <description>Self-administered erenumab via one 140 mg/mL AI/pen on day 1, day 29 and day 57 of the CHU sub-study.</description>
        </group>
        <group group_id="E10">
          <title>CHU Sub-Study Total</title>
          <description>Self-administered erenumab via two 70 mg/mL AI/pens or one 140 mg/mL AI/pen on day 1, day 29 and day 57 of the CHU sub-study.</description>
        </group>
      </group_list>
      <serious_events>
        <default_vocab>MedDRA 22.0</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, all-cause mortality</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="136"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="67"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="135"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="137"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="386"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="189"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="459"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="24"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="49"/>
              </event>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="136"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="66"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="135"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="137"/>
                <counts group_id="E5" subjects_affected="18" subjects_at_risk="386"/>
                <counts group_id="E6" subjects_affected="9" subjects_at_risk="189"/>
                <counts group_id="E7" subjects_affected="27" subjects_at_risk="459"/>
                <counts group_id="E8" subjects_affected="1" subjects_at_risk="24"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E10" subjects_affected="1" subjects_at_risk="49"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>Prinzmetal angina</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="136"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="66"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="135"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="137"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="386"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="189"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="459"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="24"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="49"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Ear and labyrinth disorders</title>
            <event_list>
              <event>
                <sub_title>Vertigo positional</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="136"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="66"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="135"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="137"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="386"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="189"/>
                <counts group_id="E7" subjects_affected="1" subjects_at_risk="459"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="24"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="49"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Eye disorders</title>
            <event_list>
              <event>
                <sub_title>Eyelid ptosis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="136"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="66"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="135"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="137"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="386"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="189"/>
                <counts group_id="E7" subjects_affected="1" subjects_at_risk="459"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="24"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="49"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Haemorrhoids</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="136"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="66"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="135"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="137"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="386"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="189"/>
                <counts group_id="E7" subjects_affected="1" subjects_at_risk="459"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="24"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="49"/>
              </event>
              <event>
                <sub_title>Diverticulum intestinal haemorrhagic</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="136"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="66"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="135"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="137"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="386"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="189"/>
                <counts group_id="E7" subjects_affected="1" subjects_at_risk="459"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="24"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="49"/>
              </event>
              <event>
                <sub_title>Enterocolitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="136"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="66"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="135"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="137"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="386"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="189"/>
                <counts group_id="E7" subjects_affected="1" subjects_at_risk="459"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="24"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="49"/>
              </event>
              <event>
                <sub_title>Large intestine polyp</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="136"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="66"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="135"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="137"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="386"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="189"/>
                <counts group_id="E7" subjects_affected="1" subjects_at_risk="459"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="24"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="49"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Gastroenteritis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="136"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="66"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="135"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="137"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="386"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="189"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="459"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="24"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="49"/>
              </event>
              <event>
                <sub_title>Intestinal tuberculosis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="136"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="66"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="135"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="137"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="386"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="189"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="459"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="24"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="49"/>
              </event>
              <event>
                <sub_title>Diverticulitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="136"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="66"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="135"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="137"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="386"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="189"/>
                <counts group_id="E7" subjects_affected="1" subjects_at_risk="459"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="24"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="49"/>
              </event>
              <event>
                <sub_title>Meningitis viral</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="136"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="66"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="135"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="137"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="386"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="189"/>
                <counts group_id="E7" subjects_affected="1" subjects_at_risk="459"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="24"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="49"/>
              </event>
              <event>
                <sub_title>Mycobacterial infection</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="136"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="66"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="135"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="137"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="386"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="189"/>
                <counts group_id="E7" subjects_affected="1" subjects_at_risk="459"/>
                <counts group_id="E8" subjects_affected="1" subjects_at_risk="24"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E10" subjects_affected="1" subjects_at_risk="49"/>
              </event>
              <event>
                <sub_title>Pharyngitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="136"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="66"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="135"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="137"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="386"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="189"/>
                <counts group_id="E7" subjects_affected="1" subjects_at_risk="459"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="24"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="49"/>
              </event>
              <event>
                <sub_title>Tonsillitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="136"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="66"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="135"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="137"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="386"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="189"/>
                <counts group_id="E7" subjects_affected="1" subjects_at_risk="459"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="24"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="49"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Injury, poisoning and procedural complications</title>
            <event_list>
              <event>
                <sub_title>Hand fracture</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="136"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="66"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="135"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="137"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="386"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="189"/>
                <counts group_id="E7" subjects_affected="1" subjects_at_risk="459"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="24"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="49"/>
              </event>
              <event>
                <sub_title>Cartilage injury</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="136"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="66"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="135"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="137"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="386"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="189"/>
                <counts group_id="E7" subjects_affected="1" subjects_at_risk="459"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="24"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="49"/>
              </event>
              <event>
                <sub_title>Clavicle fracture</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="136"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="66"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="135"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="137"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="386"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="189"/>
                <counts group_id="E7" subjects_affected="1" subjects_at_risk="459"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="24"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="49"/>
              </event>
              <event>
                <sub_title>Meniscus injury</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="136"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="66"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="135"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="137"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="386"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="189"/>
                <counts group_id="E7" subjects_affected="1" subjects_at_risk="459"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="24"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="49"/>
              </event>
              <event>
                <sub_title>Muscle rupture</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="136"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="66"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="135"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="137"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="386"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="189"/>
                <counts group_id="E7" subjects_affected="1" subjects_at_risk="459"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="24"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="49"/>
              </event>
              <event>
                <sub_title>Postoperative ileus</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="136"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="66"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="135"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="137"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="386"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="189"/>
                <counts group_id="E7" subjects_affected="1" subjects_at_risk="459"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="24"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="49"/>
              </event>
              <event>
                <sub_title>Tendon rupture</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="136"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="66"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="135"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="137"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="386"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="189"/>
                <counts group_id="E7" subjects_affected="1" subjects_at_risk="459"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="24"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="49"/>
              </event>
              <event>
                <sub_title>Tooth fracture</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="136"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="66"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="135"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="137"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="386"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="189"/>
                <counts group_id="E7" subjects_affected="1" subjects_at_risk="459"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="24"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="49"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Metabolism and nutrition disorders</title>
            <event_list>
              <event>
                <sub_title>Dehydration</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="136"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="66"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="135"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="137"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="386"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="189"/>
                <counts group_id="E7" subjects_affected="1" subjects_at_risk="459"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="24"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="49"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Systemic lupus erythematosus</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="136"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="66"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="135"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="137"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="386"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="189"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="459"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="24"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="49"/>
              </event>
              <event>
                <sub_title>Chondropathy</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="136"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="66"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="135"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="137"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="386"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="189"/>
                <counts group_id="E7" subjects_affected="1" subjects_at_risk="459"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="24"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="49"/>
              </event>
              <event>
                <sub_title>Extremity contracture</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="136"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="66"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="135"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="137"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="386"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="189"/>
                <counts group_id="E7" subjects_affected="1" subjects_at_risk="459"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="24"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="49"/>
              </event>
              <event>
                <sub_title>Osteonecrosis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="136"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="66"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="135"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="137"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="386"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="189"/>
                <counts group_id="E7" subjects_affected="1" subjects_at_risk="459"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="24"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="49"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Neoplasms benign, malignant and unspecified (incl cysts and polyps)</title>
            <event_list>
              <event>
                <sub_title>Renal cell carcinoma</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="136"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="66"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="135"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="137"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="386"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="189"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="459"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="24"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="49"/>
              </event>
              <event>
                <sub_title>Breast cancer</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="136"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="66"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="135"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="137"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="386"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="189"/>
                <counts group_id="E7" subjects_affected="1" subjects_at_risk="459"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="24"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="49"/>
              </event>
              <event>
                <sub_title>Colon adenoma</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="136"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="66"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="135"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="137"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="386"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="189"/>
                <counts group_id="E7" subjects_affected="1" subjects_at_risk="459"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="24"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="49"/>
              </event>
              <event>
                <sub_title>Intraductal proliferative breast lesion</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="136"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="66"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="135"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="137"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="386"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="189"/>
                <counts group_id="E7" subjects_affected="1" subjects_at_risk="459"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="24"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="49"/>
              </event>
              <event>
                <sub_title>Uterine leiomyoma</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="136"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="66"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="135"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="137"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="386"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="189"/>
                <counts group_id="E7" subjects_affected="1" subjects_at_risk="459"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="24"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="49"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Migraine</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="136"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="66"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="135"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="137"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="386"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="189"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="459"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="24"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="49"/>
              </event>
              <event>
                <sub_title>Headache</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="136"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="66"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="135"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="137"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="386"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="189"/>
                <counts group_id="E7" subjects_affected="1" subjects_at_risk="459"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="24"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="49"/>
              </event>
              <event>
                <sub_title>Intracranial aneurysm</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="136"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="66"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="135"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="137"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="386"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="189"/>
                <counts group_id="E7" subjects_affected="1" subjects_at_risk="459"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="24"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="49"/>
              </event>
              <event>
                <sub_title>Myelopathy</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="136"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="66"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="135"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="137"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="386"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="189"/>
                <counts group_id="E7" subjects_affected="1" subjects_at_risk="459"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="24"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="49"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Psychiatric disorders</title>
            <event_list>
              <event>
                <sub_title>Depression</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="136"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="66"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="135"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="137"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="386"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="189"/>
                <counts group_id="E7" subjects_affected="1" subjects_at_risk="459"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="24"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="49"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Reproductive system and breast disorders</title>
            <event_list>
              <event>
                <sub_title>Cervical dysplasia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="136"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="66"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="135"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="137"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="386"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="189"/>
                <counts group_id="E7" subjects_affected="1" subjects_at_risk="459"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="24"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="49"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <default_vocab>MedDRA 22.0</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="55" subjects_at_risk="136"/>
                <counts group_id="E2" subjects_affected="28" subjects_at_risk="66"/>
                <counts group_id="E3" subjects_affected="67" subjects_at_risk="135"/>
                <counts group_id="E4" subjects_affected="58" subjects_at_risk="137"/>
                <counts group_id="E5" subjects_affected="231" subjects_at_risk="386"/>
                <counts group_id="E6" subjects_affected="133" subjects_at_risk="189"/>
                <counts group_id="E7" subjects_affected="343" subjects_at_risk="459"/>
                <counts group_id="E8" subjects_affected="7" subjects_at_risk="24"/>
                <counts group_id="E9" subjects_affected="7" subjects_at_risk="25"/>
                <counts group_id="E10" subjects_affected="14" subjects_at_risk="49"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Abdominal pain upper</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="136"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="66"/>
                <counts group_id="E3" subjects_affected="5" subjects_at_risk="135"/>
                <counts group_id="E4" subjects_affected="2" subjects_at_risk="137"/>
                <counts group_id="E5" subjects_affected="22" subjects_at_risk="386"/>
                <counts group_id="E6" subjects_affected="4" subjects_at_risk="189"/>
                <counts group_id="E7" subjects_affected="26" subjects_at_risk="459"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="24"/>
                <counts group_id="E9" subjects_affected="1" subjects_at_risk="25"/>
                <counts group_id="E10" subjects_affected="1" subjects_at_risk="49"/>
              </event>
              <event>
                <sub_title>Constipation</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="136"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="66"/>
                <counts group_id="E3" subjects_affected="7" subjects_at_risk="135"/>
                <counts group_id="E4" subjects_affected="7" subjects_at_risk="137"/>
                <counts group_id="E5" subjects_affected="14" subjects_at_risk="386"/>
                <counts group_id="E6" subjects_affected="5" subjects_at_risk="189"/>
                <counts group_id="E7" subjects_affected="19" subjects_at_risk="459"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="24"/>
                <counts group_id="E9" subjects_affected="1" subjects_at_risk="25"/>
                <counts group_id="E10" subjects_affected="1" subjects_at_risk="49"/>
              </event>
              <event>
                <sub_title>Dental caries</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="136"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="66"/>
                <counts group_id="E3" subjects_affected="7" subjects_at_risk="135"/>
                <counts group_id="E4" subjects_affected="2" subjects_at_risk="137"/>
                <counts group_id="E5" subjects_affected="17" subjects_at_risk="386"/>
                <counts group_id="E6" subjects_affected="9" subjects_at_risk="189"/>
                <counts group_id="E7" subjects_affected="26" subjects_at_risk="459"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="24"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="49"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Gastroenteritis</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="136"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="66"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="135"/>
                <counts group_id="E4" subjects_affected="4" subjects_at_risk="137"/>
                <counts group_id="E5" subjects_affected="27" subjects_at_risk="386"/>
                <counts group_id="E6" subjects_affected="15" subjects_at_risk="189"/>
                <counts group_id="E7" subjects_affected="41" subjects_at_risk="459"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="24"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="49"/>
              </event>
              <event>
                <sub_title>Nasopharyngitis</sub_title>
                <counts group_id="E1" subjects_affected="41" subjects_at_risk="136"/>
                <counts group_id="E2" subjects_affected="22" subjects_at_risk="66"/>
                <counts group_id="E3" subjects_affected="39" subjects_at_risk="135"/>
                <counts group_id="E4" subjects_affected="45" subjects_at_risk="137"/>
                <counts group_id="E5" subjects_affected="174" subjects_at_risk="386"/>
                <counts group_id="E6" subjects_affected="109" subjects_at_risk="189"/>
                <counts group_id="E7" subjects_affected="274" subjects_at_risk="459"/>
                <counts group_id="E8" subjects_affected="5" subjects_at_risk="24"/>
                <counts group_id="E9" subjects_affected="6" subjects_at_risk="25"/>
                <counts group_id="E10" subjects_affected="11" subjects_at_risk="49"/>
              </event>
              <event>
                <sub_title>Pharyngitis</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="136"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="66"/>
                <counts group_id="E3" subjects_affected="5" subjects_at_risk="135"/>
                <counts group_id="E4" subjects_affected="3" subjects_at_risk="137"/>
                <counts group_id="E5" subjects_affected="22" subjects_at_risk="386"/>
                <counts group_id="E6" subjects_affected="7" subjects_at_risk="189"/>
                <counts group_id="E7" subjects_affected="28" subjects_at_risk="459"/>
                <counts group_id="E8" subjects_affected="1" subjects_at_risk="24"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E10" subjects_affected="1" subjects_at_risk="49"/>
              </event>
              <event>
                <sub_title>Cystitis</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="136"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="66"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="135"/>
                <counts group_id="E4" subjects_affected="2" subjects_at_risk="137"/>
                <counts group_id="E5" subjects_affected="18" subjects_at_risk="386"/>
                <counts group_id="E6" subjects_affected="8" subjects_at_risk="189"/>
                <counts group_id="E7" subjects_affected="26" subjects_at_risk="459"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="24"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="49"/>
              </event>
              <event>
                <sub_title>Influenza</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="136"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="66"/>
                <counts group_id="E3" subjects_affected="3" subjects_at_risk="135"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="137"/>
                <counts group_id="E5" subjects_affected="46" subjects_at_risk="386"/>
                <counts group_id="E6" subjects_affected="29" subjects_at_risk="189"/>
                <counts group_id="E7" subjects_affected="75" subjects_at_risk="459"/>
                <counts group_id="E8" subjects_affected="1" subjects_at_risk="24"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E10" subjects_affected="1" subjects_at_risk="49"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Back pain</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="136"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="66"/>
                <counts group_id="E3" subjects_affected="7" subjects_at_risk="135"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="137"/>
                <counts group_id="E5" subjects_affected="28" subjects_at_risk="386"/>
                <counts group_id="E6" subjects_affected="7" subjects_at_risk="189"/>
                <counts group_id="E7" subjects_affected="34" subjects_at_risk="459"/>
                <counts group_id="E8" subjects_affected="1" subjects_at_risk="24"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E10" subjects_affected="1" subjects_at_risk="49"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>The Clinical Trial Agreement generally does not restrict an investigator's discussion of trial results after completion. The Agreement permits Amgen a limited period of time to review material discussing trial results (typically up to 45 days and possible extension). Amgen may remove confidential information, but authors have final control and approval of publication content. For multicenter studies, the investigator agrees not to publish any results before the first multi-center publication.</restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Study Director</name_or_title>
      <organization>Amgen Inc.</organization>
      <phone>866-572-6436</phone>
      <email>medinfo@amgen.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

